Textbook of Pulmonary Medicine (2 Volumes) D Behera
INDEX
A
A1-antitrypsin augmentation therapy 1136
A1-antitrypsin deficiency screening 1129
AB rotation or cycling policy 1782
Abnormal branching 1678
Abnormal breathing patterns 27
Abnormal radiological findings 142
Abnormal ventilatory impedance 27
Abnormalities of ventilation 107
aerodynamic filtration 111
airway reflexes 112
bronchoconstriction 112
cough 112
alveolar hypoventilation 108
apneustic breathing 109
Biot’s breathing (ataxic breathing) 109
Cheyne-Stokes respiration 109
hyperventilation 107
modes of action of nonspecific defenses in the lung 115
local detoxification 115
mechanical earners 115
physical transport 115
nonspecific mechanisms 111
Ondine’s curse 109
phagocytosis 115
Pickwickian syndrome 109
tracheobronchial secretions and mucociliary clearance 112
mucus 112
nonspecific soluble factors in tracheobronchial secretion 113
cilia and mucociliary function 113
Accelerated silicosis 1469
Acid-base balance 88, 91
buffering in body system 89
clinical disorders and therapy of acid-base balance 91
metabolic acidosis 92
respiratory acidosis 91
respiratory alkalosis 92
determination of acid-base status 90
compensatory mechanisms 90
metabolic alkalosis 93
combined disorders 93
Acid-base status 90
Acinetobacter pneumonia 359
Acquired (secondary) drug resistance 552
Acquired drug resistance 555
initial drug resistance 555
Acquired immunodeficiency syndrome 216
Actinomycosis 832
clinical features 833
treatment 833
Acute asthma in adults 998
criteria for admission 999
criteria for referral 999
initial assessment 998
prevention of acute deterioration 999
recognition of acute asthma 998
self treatment by patients developing acute or uncontrolled asthma 998
treatment of acute asthma in adults 999
antibiotics 1001
beta2-agonist bronchodilators 999
further investigation and monitoring 1001
heliox 1001
intravenous aminophylline 1000
intravenous fluids 1001
intravenous magnesium sulphate 1000
ipratropium bromide 1000
leukotriene receptor antagonists 1001
noninvasive ventilation 1001
oxygen 999
referral to intensive care 1001
steroid therapy 1000
Acute asthma in children aged over 2
years 1002
initial assessment 1002
Acute cor pulmonale 1200
Acute coryza 380
Acute cough 18
Acute exacerbation of chronic respiratory failure 1175
Acute exacerbations or bronchitis 439, 1162
Acute interstitial pneumonia 1255
Acute interstitial pneumonia or Hamman-rich syndrome 1255
Acute otitis media 1704
Acute pharyngitis 1704
Acute pharyngitis and tonsillitis 382
Acute respiratory distress syndrome 216
Acute respiratory infections (ARI) 1701
in India 1702
acute otitis media 1704
acute sinusitis 1704
infectious croup 1704
sore throat (acute pharyngitis/tonsillitis) 1704
Acute severe asthma (status asthmaticus) 961
assessment of severity 964
clinical features 962
indications for admission in intensive care unit 969
pathophysiology 962
therapeutic management 965
Acute silicosis 1469
Acute sinusitis 1704
Acute unexplained dyspnea 1201
Acyclovir 273
Add-on therapy 991
Adenocarcinoma 1311
Adenoid cystic carcinoma 1374
Adenosine receptor antagonism 924
Adenovirus pneumonia 395
Adhesion molecules 124, 888
Aerodynamic filtration 111
Age and ethnicity 919
Agenesis 1678
Agriculture 1528
Air pollution 1078, 1157, 1307
Airflow limitation 1129
Airspace disease 146
Airway involvement 1448
Airway management 1772
Airway obstruction in COPD 1082
Airway pathology 906
Airway reflexes 112
Airway remodeling 905
Airway resistance 73, 74
Airway submucosa 117, 1772
Airway suctioning 1772
Airways inflammation 899
airway pathology during asthma remission 906
aspirin-induced asthma 901
exercise-induced asthma 902
noctural asthma 904
occupational asthma 903
virus-induced asthma 902
Allergens 872
Allergic bronchopulmonary aspergillosis 809
differential diagnosis 815
laboratory findings 814
pathophysiology 809
radiology 810
treatment 816
Allergic granulomatosis 1425
Allergic rhinitis 1027
Allergy 870, 921
Alternative systems of medicine 1028
Alternative treatment for oral steroid dependence 942
Aluminium and lungs 1541
Alveolar epithelium 53
Alveolar hypoventilation 108
Alveolar oxygen tension (PaO2) 85
Alveolar period 45
Alveolar pores of Kohn 56
Alveolar ventilation 65
Amantadine 274
Ambulatory care 720
Amikacin 263, 717
Aminoglycoside antibiotics 261
classic adverse effects of aminoglycosides 262
gentamicin 263
adverse reactions 263
kanamycin and neomycin 263
spectinomycin 263
general comments about aminoglycosides 263
development of resistance to aminoglycosides 264
spectrum of activity and clinical uses 262
streptomycin 263
adverse reactions 263
tobramycin 263
adverse reactions 263
Aminoglycosides 262264, 717
Ammonia 1545
Amphotericin B 270, 834
side effects 835
newer lipid formulations 835
Amyloidosis 511
Anaerobic threshold 204
Anatomic distribution 160
Anemia 1
Anesthesia and lung 226
physiologic alterations with anesthesia and surgery 227
postoperative pulmonary complication 227
risk factors for postoperative pulmonary complications 227
preoperative risk factors 227
intraoperative factors 228
postoperative factors 228
Anesthesia and surgery 227
Angiitis 1425
Angiography 187
Ankylosing spondylitis 1456, 1660
Anomalies of tracheobronchial tree 1673
abnormal branching 1678
agenesis and hypoplasia of lung 1678
anomalies of pulmonary vasculature 1681
anomalous venous drainage of lung 1681
pulmonary arteriovenous malformation 1681
pulmonary artery stenosis 1681
azygos lobe 1680
bronchogenic cysts 1678
congenital cystic malformations of lung 1679
sequestration of lung 1680
tracheal agenesis and atresia 1673
tracheal diverticuli 1674
tracheal stenosis 1673
tracheobronchomalacia 1676
cine magnetic resonance imaging 1676
dynamic CT 1676
dynamic flexible videobronchoscopy 1677
morphometric videobronchoscopy 1677
tracheobronchomegaly (Mounier-Kuhn syndrome) 1674
tracheoesophageal fistula 1673
tracheopathia osteoplastica 1677
Anterior mediastinal nodes 59
Anteroposterior (AP) view 135
Antibiotic pressure 1782
Antibiotic resistance in ICU 1781
beta lactamases 1781
Antibiotic therapy 242
Antibiotics 267, 1001, 1136, 1140, 1141
Antibody effector functions 130
Anticholinergics 933
rationale for the use of anticholinergics 933
Anticoagulant therapy 1210
monitoring of oral anticoagulant therapy 1210
Anti-fibrotic drugs 1270
Antifungal antibiotics 269
amphotericin B 270
echinocandins (caspofungin) 273
fluconazole 273
flucytosine 271
itraconazole 273
ketoconazole 272
liposomal amphotericin B 271
miconazole 272
voriconazole 273
Antigen 285
Antigen and immune defence in lungs 121
Antigen presenting cells 120
Antigen reacting cells 120
Antigen recognition by GD T cells 127
Antihistamines 940
Anti-IGE monoclonal antibody 994
Anti-immunoglobulin E 982
Anti-inflammatory agents 1269
Anti-inflammatory effect 924
Anti-interleukin-5 antibodies 984
Antineutrophil cytoplasmic antibodies 1421
Antioxidant agents 1136
Antioxidant systems 116
Antituberculosis therapy 607
Antitussives 1136
Antiviral agents 380
Antiviral drugs 273
acyclovir 273
amantadine 274
ganciclovir 275
vidarabine/ARA-A 273
zidovudine or azidothymidine 275
ANTM disease 794
Apicogram 136
Apneustic breathing 109
Apneustic center 94
Apoptosis 116
Approach to staging of lung cancer 1336
Arachidonic acid products 1228
ARDS management 1780
ARI in India 1702
Arterial and venous CO2 88
Arterial blood gas measurement 1129, 1139
Arterial blood gases 1203
Arterial blood oxygen content (CaO2) 87
Arterial oxygen tension (PaO2) 85
Arterial puncture for blood gas analysis 1775
procedure 1775
purpose 1775
Arthralgia 718
Asbestos 1495, 1507
Asbestos exposure 1504
Asbestos problem in India 1518
Asbestos related diseases 1494
asbestosis 1502
clinical features 1503
investigations 1503
lung cancer 1505
pathogenesis and pathology 1501
physical and chemical characteristics of asbestos 1495
exposure 1496
pleural disease 1501
pleural effusion 1500
pleural plaques 1497
diffuse pleural thickening and diffuse pleural fibrosis 1499
pulmonary function changes and asbestos exposure 1504
rounded atelectasis 1499
treatment 1504
Asbestosis 1502
Aspergilloma 816
clinical features 817
diagnosis 817
mycetoma and HIV-infection 819
treatment 817
Aspergillosis 805
Aspiration pneumonia 213, 306309
bacteriology of aspiration pneumonia 307
clinical features 309
diagnosis of aspiration pneumonia 309
pathogenesis and pathology of aspiration pneumonia 308
prognosis and natural course 310
treatment 310
Aspiration syndromes 1548
Aspirin intolerant asthma 994
Aspirin-induced asthma 901
Assessment of activity of sarcoidosis 1403
Assessment of acute asthma in children aged less than 2
years 1005
Assessment of symptoms 1128
additional investigations 1129
a1-antitrypsin deficiency screening 1129
arterial blood gas measurement 1129
bronchodilator reversibility testing 1129
chest X-ray 1129
assessment of COPD severity 1129
differential diagnosis 1129
measurement of airflow limitation 1129
medical history 1128
ongoing monitoring and assessment 1130
physical examination 1129
smoking cessation intervention process 1131
smoking prevention and cessation 1131
Asthma care 1010
Asthma control 1013
Asthma in children 1739
Asthma in special situations 1026
allergic rhinitis, nasal polyps and sinusitis 1027
cardiovascular diseases 1028
gastroesophageal reflux disease 1028
pregnancy 1026
surgery 1027
Asthma mortality 917
Asthma remission 906
Asthma therapy 1740
Asthmatic bronchitis 1073
a1-antitrypsin deficiency 1077
air pollution 1078
bronchial hyperresponsiveness 1080
childhood lung diseases 1079
occupation 1079
passive smoking 1077
smoking 1075
Ataxic breathing 109
Atopy 870
Atopy and allergy 870
different allergens 872
drugs 875
endocranial factors 881
exercise-induced asthma 875
food allergen and breastfeeding 873
gastroesophageal reflux 879
genetics and asthma 881
infection 874
occupation and asthma 876
pollution 880
psychological factors 879
rhinitis and sinusitis 878
tartrazine and sulfite sensitivity 878
Attenuated mycobacteria 575
Atypical pneumonias 366
Auscultation 5
Autonomic ganglionic tumors 1641
Avian influenza 390
Azalide antibiotics 266
Azidothymidine (AZT) 275
Azole 835
Azygos lobe 1680
B
B cells and infection B cell activation 128
B2 agonist bronchodilators 1005
Bacilli on smear examination 514
Bacillus pneumonia (anthrax) 338
clinical features 338
cutaneous 338
gastrointestinal 339
inhalational 338
decontamination 339
diagnosis 339
infection control 339
pathogenesis 338
treatment of inhalation anthrax 339
Bacitracin 261
Bacterial flora 280
Bacterial pneumonias 1707
Bacteriology 544
Baritosis 1541
Barometric pressures 102, 103
Basophils 888
B-blockers 993
BCG test 530
BCG vaccination 605
Behçet’s syndrome 1460
Berylliosis 1533
Beta lactamases 1781
Beta2-agonist bronchodilators 999
Beta-adrenergic agonists 927
biochemistry 929
mechanisms of action 929
normal beta-adrenergic receptor physiology 927
optimal pharmacological profile of beta-adrenoceptor agonists 930
side effects 931
some controversial facts about B2-agonists 932
Beta-adrenergic receptors(BAR) and asthma 898
Beta-adrenoceptor agonists 930
Beta-lactam antibiotics 248
inhibitors of cell wall synthesis 248
mechanism of action 248
resistance to beta-lactam antibiotics 248
Beta-lactams (cephalosporins) 254
cefaclor 255
cefadroxil 255
cefamandoles 255
cefazolin 255
cefixime 256
cefonicid 256
cefoperazone 257
ceforanide 256
cefotaxime 256
cefotetan 256
cefoxin 255
ceftazidime 256
ceftizoxime 257
ceftriaxone 257
cefuroxime 256
cephalexin 255
cephalothin 255
cephapirin 255
cephradine 255
other B-lactam containing antibacterials 258
moxalactam 258
Bhopal gas tragedy 1550
Biochemical measurements 1566
Biochemistry 929
Biological weapon 373
Biology of lung cancer 1314
Biopsy 1400
Biopsy procedures 1402
Biot’s breathing 109
B-lactam containing antibacterials 258
Blastomycosis 827
clinical features 827
diagnosis 827
pathophysiology 827
treatment 828
Blood culture 285
Blood flow 80
Blood gas abnormalities 27
Blood transfusions 1779
Blood vessels 41
Body plethysmographic method 69
Borg scale 30
Bradykinin 891
Breastfeeding 873, 986
Breathing disorders during sleep 104
clinical features of sleep apnea 105
investigations of sleep apnea 106
treatment 106
treatment of central sleep apnea 107
treatment of obstructive sleep apnea 107
sleep apnea syndrome 104
obstructive sleep apnea 104
Brittle asthma 909
Broad spectrum penicillins 253
adverse reactions to penicillins 253
Broken vials 621
Bronchi 48
Bronchial asthma 1730
air pollution 1736
diagnosis 1737
diet 1735
evolution of asthma 1736
infants and children 1737
miscellaneous 1738
obstruction in large airways 1737
obstruction involving both large and small airways 1737
international scene 1730
intrauterine exposure 1734
prevalence 1730
protective infections 1735
viral infection 1735
Bronchial asthma 216, 882, 906, 920
Bronchial circulation 56
Bronchial histology 50
Bronchial hyperreactivity 883, 896
Bronchial hyperresponsiveness 1080
Bronchial mucosa 122
Bronchiectasis 439, 509, 1442
Bronchiolitis 1442, 1705
Bronchiolitis obliterans with organizing pneumonia (BOOP) 1274
clinical features 1275
pathogenesis and pathology 1274
treatment 1276
Bronchitis 1491
Bronchoalveolar lavage 213, 1264
method 213
normal values 214
potential uses of BAL 215
acquired immunodeficiency syndrome 216
acute respiratory distress syndrome 216
bronchial asthma 216
interstitial lung diseases 215
lung cancer 217
occupational lung diseases 216
pneumonias 217
smoking 215
Bronchocentric granulomatosis 1429
Bronchoconstriction 112
Bronchodilator reversibility testing 1129
Bronchodilator test 197
Bronchodilator therapy 1140
Bronchogenic carcinoma 507
Bronchogenic cysts 1643
Bronchography 186
Broncholiths 1475
Bronchoprovocation tests 198
Bronchopulmonary hygiene 440
Bronchoscopic treatment 1344
Bronchoscopy 1333
Bullae 157
Bullectomy/LVRS 221
Byssinosis 1526
agriculture 1528
clinical features 1529
diagnosis 1530
lung function tests 1530
fabric manufacturing 1529
occupation 1528
pathogenesis 1529
pathology 1529
textile waste 1529
thread mills 1529
treatment 1530
yarn manufacturing 1528
C
Calcification 158
Calcium ion flux 924
Canalicular period 44
Canals of Lambert 56
Cancer and lung defence 124
antibody effector functions 130
antigen recognition by GD T cells 127
B cells and infection B cell activation 128
cytokine production by GD T cells 127
humoral immunity within lung 130
immunoglobulin isotypes 129
ontogeny of GD T cells 126
regulation of T cell subset development 125
innate immune cells 125
role of GD T cells during infection 128
role of interleukin-12 125
T cell expansion and differentiation leads to the generation of effector cells 126
T cell subsets 125
Cancer and lung defence 124
Candidiasis 823
diagnosis 824
treatment 824
Caplan’s syndrome 1442
Capreomycin 539
Carbapenems 259
bacitracin 261
adverse effects 261
major clinical use 261
clavulanic acid 260
cycloserine 261
major clinical use 261
membrane-active agents 261
clinical applications of polymixin B 261
gramicidin 261
polymixins 261
other inhibitors of cell wall synthesis 260
major clinical use 260
vancomycin 260
Carbon dioxide removal 103
Carbon dioxide response curves 96
Carbon dioxide transport 87
Carbon monoxide (CO) 1544
Carcinoid tumor 1370
Carcinosarcoma 1374
Cardiac parameters 204
Cardiogenic pulmonary edema 1176
Cardiopulmonary exercise testing 202
Cardiovascular diseases 1028
Cardiovascular effect 98
Caspofungin 273
Catastrophic antiphospholipid syndrome 1449
Catecholamine release 924
Cavity 155
Cefaclor 255
Cefadroxil 255
Cefamandoles 255
Cefazolin 255
Cefixime 256
Cefonicid 256
Cefoperazone 257
Ceforanide 256
Cefotaxime 256
Cefotetan 256
Cefoxin 255
Ceftazidime 256
Ceftizoxime 257
Ceftriaxone 257
Cefuroxime 256
Cell wall synthesis 248
Cell-mediated cytotoxicity 121
Cellular contents 1564
Central chemoreceptors 94
Central respiratory control 93
Central sleep apnea 107
Cephalexin 255
Cephalothin 255
Cephapirin 255
Cephradine 255
Changes in RNTCP (India) policy on diagnosis of smear-positive pulmonary TB 759
number of sputum specimen 759
Chemical injuries 1545
Chemical stimuli 95
Chemoprophylaxis 605
Chemoreceptors 26
Chemotherapy 1336
Chemotherapy and novel targeted therapy for lung cancer 1345
Chemotherapy of tuberculosis 540
bacteriology (result of sputum smear) 544
history of previous treatment 545
chronic case 545
new case 545
relapse 545
treatment after interruption (TAI) or return after default 545
treatment failure 545
rationale for recommended treatment regimens 545
severity of disease 544
site of tubercular disease 544
supervision of chemotherapy 547
Chest imaging techniques 1399
Chest pain 23
emotional disorders 24
mediastinal pain 23
pleuropulmonary 23
referred pain 23
Chest skiagram 1322
Chest trauma 221
Chest wall 71
Chest wall and thoracic cage abnormalities 1656
Chest wall pain 23
Chest wall receptors 26
Cheyne-Stokes respiration 109
Chickenpox pneumonia 396
Childhood lung diseases 1079
Chloramphenicol 268
Chlorine 1546
Chlortetracycline 266
Chromium related lung diseases 1536
Chronic beryllium disease (CBD) 1533
Chronic bronchial asthma 947
Chronic bronchitis 1071
Chronic cough 19
Chronic lung diseases and lung cancer 1307
Chronic mountain sickness 102
Chronic necrotizing aspergillosis 819
clinical presentation 819
diagnosis 819
treatment 819
Chronic neuromuscular disease 1179
Chronic obstructive pulmonary diseases 1071
Chronic persistent asthma 955
Chronic respiratory failure 1178
Chronic silicosis 1469
Churg-Strauss syndrome (CSS) 1425
clinical features 1425
diagnosis 1426
histology 1426
imaging 1425
other investigations 1425
treatment 1427
Chylothorax 220
Cytokines 124
adhesion molecules 124
Cilia and mucociliary function 113
Cine magnetic resonance imaging 1676
Classification of asthma 916
Classification of asthma by level of control 1010, 1748
Clavulanic acid 260
Clindamycin 267
Clinical consequences of pleural effusion 1559
Clinical evaluation of ARDS 1232
chest radiography 1232
computed tomography 1233
evaluation of gas exchange 1234
hemodynamic monitoring 1234
measurement of lung injury 1234
other useful parameters 1235
Clinical presentation of bronchial asthma 906
intrinsic and extrinsic asthma 907
late onset asthma 907
nocturnal asthma 909
occupational asthma 908
Clubbing 2
CO2 dissociation curve 88
Coagulation products and lung injury 1227
Coal workers’ pneumoconiosis 1480
bronchitis and emphysema 1491
chest radiographic features 1488
clinical features 1487
complications and prognosis 1490
diagnosis 1490
disability and natural history 1491
investigations 1487
pathogenesis and pathology of CWP 1483
silicosis 1491
treatment 1490
types of respiratory problems in coalworkers 1483
Coccidioidomycosis 828
clinical features 828
disseminated coccidioidomycosis 829
primary infection 828
diagnosis 829
treatment 829
Combating antibiotic resistance 1781
Combination inhalers 992
Common cold (acute coryza) 380
clinical features and diagnosis 381
epidemiology and etiology 380
pathogenesis and pathology 381
treatment 382
Community-acquired pneumonias 288
clinical stability and discharge 297
course and outcome 296
when DRSP is a concern 292
both OPD/non-ICU patients 293
indoor patients 292
OPD patients 292
Comorbidities 1144
Complications of tuberculosis 507
amyloidosis 511
aspergilloma (mycetoma; “fungus ball”) 508
bronchiectasis 509
calcification 510
cor pulmonale 512
hemoptysis 507
open negative syndrome 511
physiological changes 511
respiratory failure 512
scar carcinoma 511
spontaneous pneumothorax 510
tuberculous endobronchitis and tracheitis 510
tuberculous laryngitis and enteritis 510
Computerized systems 731
Congenital anatomic defects 431
Congenital cystic malformations of lung 1679
Congenital kyphoscoliosis 1657
Congenital tuberculosis 495
Congestive cardiac failure 1569
Connective tissue 40
Connective tissue disease 1458
Conservative approach 1601
Continuous positive airway pressure 1176
Contraindications for cardiopulmonary exercise testing 202
absolute contraindications 202
complications of exercise test 205
relative contraindications 202
anaerobic threshold 204
cardiac parameters 204
end tidal O2 and CO2 205
interpretation 205
ventilation parameters 204
Complications of thoracoscopy 221
medical thoracoscopy 221
videoassisted thoracoscopic surgery (VATS) 221
procedure 221
Contraindications of thoracoscopy 221
Control of ventilation 93
central respiratory control 93
apneustic center 94
medullary respiratory center 94
pneumotaxic center 94
effectors 96
sensors 94
central chemoreceptors 94
interaction of chemical stimuli 95
lung receptors 95
other receptors 96
peripheral chemoreceptors 94
Conventional tomography 162
COPD and air travel 1105
COPD and bronchial asthma 915
COPD severity 1129
Cor pulmonale 512
Corticosteroid in tuberculosis 549
Corticosteroids 935
side effects 939
Costochondritis 1663
Cough 16
acute cough 18
chronic cough 19
complications of cough 21
diagnostic evaluation 18
subacute cough 19
treatment 19
specific therapy 19
symptomatic therapy 19
Cricoarytenoid arthritis 1443
Critical care in pulmonary diseases 1771
Cromolyn sodium 939
Cromones 939
Cryptococcosis 830
clinical features 831
diagnosis 831
treatment 831
CT scan 1323
Cutaneous reactions 718
Cyclosporine 1270
Cycloserine 261, 538, 718
side effects 539
Cylindroma (adenoid cystic carcinoma) 1374
Cyst 157
Cystic fibrosis 433, 445, 448
clinical features 447
pathogenesis 446
respiratory system 447
Cytokine production by GD T cells 127
Cytokine-directed therapy 984
Cytokines 124, 891
Cytokines in bronchial asthma 888
Cytology 1333
Cytomegalovirus pneumonia 394
clinical presentation 394
diagnosis 395
treatment 395
D
D-dimer test 1204
Dead space 65
Decompression sickness 103
Decontamination 339, 705
Demeclocycline 266
Demographic and other variables 1080
Demonstration of bacilli on smear examination 514
collection of specimen 514
culture of mycobacteria 518
decontamination of specimens 515
drug susceptibility testing 519
newer technologies 520
chemical detection of biological compounds 522
genetic probes 520
immunodiagnosis of tuberculosis 521
miscellaneous methods 523
mycobacteriophage typing 522
radiometric methods 520
staining and microscopic examination 515
Desquamative interstitial pneumonia 1254
Diabetes mellitus 548
Diagnosing asthma 1009, 1747
Diagnosis and assessment of severity 1139
assessment of severity 1139
chest X-ray and ECG 1139
medical history 1139
other laboratory tests 1139
pulse oximetry and arterial blood gas measurement 1139
spirometry and PEF 1139
Diagnosis of occupational asthma 915
Diagnosis of pulmonary tuberculosis 591
identification of tuberculosis suspects 591
case finding tools 591
case-finding methods 592
diagnosis by sputum microscopy 592
guidelines for collecting sputum for smear microscopy 592
smear preparation, staining and reading 592
Diagnosis of smear PTB 760
Diagnosis of tuberculosis 514
Diaphragm 1664
diaphragmatic disorders 1664
diaphragmatic hernias 1664
morgagni hernia 1665
traumatic hernias 1665
eventration of diaphragm 1665
diaphragmatic paralysis 1666
Diaphragmatic disorders 1664
Diaphragmatic hernias 1664
Diaphragmatic paralysis 1666
Diarylquinoline TMC 583
Diet 1306
Dietary manipulation 989
Dietary modifications 986
Differential diagnoses 1139
antibiotics 1140
hospital management 1140
antibiotics 1141
bronchodilator therapy 1140, 1141
controlled oxygen therapy 1141
diagnosis 1144
comorbidities 1144
implementation of COPD guidelines 1145
reducing exposure to risk factors 1144
respiratory symptoms 1144
spirometry 1144
glucocorticosteroids 1140
home management 1140
hospital discharge and follow-up 1143
respiratory stimulants 1142
ventilatory support 1142
noninvasive mechanical ventilation 1142
invasive mechanical ventilation 1142
Differential diagnosis of tuberculosis 507
bronchogenic carcinoma 507
lung abscess 507
pneumonia 507
pulmonary infarction 507
Diffuse pleural fibrosis 1499
Diffuse pleural thickening 1499
Diffusion 82
Diffusion capacity 83
Digestion 705
Directly observed treatment (DOT) 601, 721
Disability and natural history 1491
Disease factors 994
Disease progression and prognosis 1164
Disease severity 1072
Disseminated NTM disease 794
DNA gyrase inhibitors 264
fluoroquinolones 264
side effects 265
side effects of tetracyclines 266
tetracyclines 265
chlortetracycline 266
demeclocycline 266
doxycycline 266
methacycline 266
minocycline 266
oxytetracycline 266
tetracycline hydrochloride 265
Docetaxel-platinum-based doublets 1347
Donor selection 1690
DOTS in TB-HIV 607
DOTS package 688
DOTS-plus 688
background 688
DOTS-plus framework for management of multidrug-resistant TB 692
sustained political and administrative commitment 692
diagnosis of drug-resistant TB through quality assured, timely culture and DST 692
magnitude of the MDR-TB problem in India 689
drug resistance 689
multi-drug resistant tuberculosis and DOTS-plus 690
special considerations for DOTS-plus 690
objectives 688, 692
recent developments 688
addressing the sources of MDR-TB 689
causes of drug-resistant tuberculosis 689
expansion of the DOTS package 688
integration of TB services 689
introduction of DOTS-plus 688
prevention of MDR-TB 688
DOTS-plus framework for the management of multidrug-resistant TB 692
DOTS-plus site committee 747
DOTS-plus treatment card 728
Doxycycline 266
Dressler’s syndrome 1584
Drotrecogin alfa 1779
Drug induced pleural effusions 1583
Drug resistance and tuberculosis 552
Drug resistance in India 554
Drug resistance surveillance 620
Drug resistance to S. pneumoniae 328
Drug resistant cases 697
Drug susceptibility testing 519, 707
Drug treatment 1161
Drug-induced alveolitis 1281
Drug-induced asthma 981
Drug-resistant tuberculosis 552, 689
Drugs 875
Drugs and their dosage 598
Dry powder inhalers 945
DST methods 707
DVT 1206
Dynamic CT 1676
Dynamic flexible videobronchoscopy 1677
Dyspnea 24, 26, 27
blood gas abnormalities 27
causes of dyspnea 27
borg scale 30
six minute walk test 30
mechanism of dyspnea 24
pathophysiology of dyspnea 26
abnormal breathing patterns 27
abnormal ventilatory impedance 27
heightened ventilatory demand 26
respiratory muscle abnormalities 27
physiology of dyspnea 25
chemoreceptors 26
chest wall receptors 26
pulmonary vagal receptors 26
respiratory motor command corollary discharge 25
positional dyspnea 27
treatment 30
altered central perception 34
decreasing central drive 31
reducing ventilatory impedance 33
E
Early asthmatic reaction (EAR) 882
ECG 1203
Echinocandins 273
Echocardiography 1204
Edema 1
Effector B cells 121
Electrocardiogram 1191
Emaciation 1
Embryonic period 43
Emotional disorders 24
Emphysema 1071, 1491
Empiric antibiotic therapy 1783
Empyema 220
Empyema thoracic 1590
End tidal O2 and CO2 205
Endobronchial ultrasound (EBUS) 225
Endocranial factors 881
Endoscopic ultrasound (EUS) 225
Endothelium 54
Enterobacter pneumonia 351
Enterogenous cysts 1643
Environmental control and prevention of asthma 1741
Eosinophilic granuloma 1377
Eosinophils 885
Epidemiology of drug-resistant tuberculosis 552
the global scene 552
Epidemiology of pneumonia 279
Epithelial cells 888
Epithelial tumors 1370
Escherichia coli pneumonia 354
Ethambutol 536
Ethionamide 539
Evaluation of response to treatment 551
Eventration of diaphragm 1665
Exacerbation asthma 993, 1022
Exacerbations 1017
Examination of chest 4
anatomical diagnosis 7
auscultation 5
etiological diagnosis 7
inspection 4
mechanisms of production of lung sounds 6
morphological diagnosis 7
palpation 4
percussion 5
Exercise capacity 202
Exercise test 200, 205
Exercise-induced asthma 875, 973
Expectorated sputum 283
Expiration 69
Expiratory skiagrams 136
Exposure 1496
Extensively drug resistant tuberculosis 477
External quality assessment (EQA) 596
Extrapulmonary effects 924
Extrapulmonary manifestations 447
Extrapulmonary tuberculosis 503, 605
Extrathoracic lesions 197
Extrinsic allergic alveolitis 809
Extrinsic asthma 808
Exudative pleural effusions 1571
diseases of lymphatics 1586
drug induced pleural effusions 1583
gastrointestinal causes of pleural effusion 1585
immunologically mediated pleural effusions 1581
lymphoma 1579
malignant mesothelioma 1580
malignant pleural effusion 1577
miscellaneous causes of pleural effusion 1588
parapneumonic effusions 1575
parasitic pleural effusions 1576
pleural effusion due to other organisms 1576
postcardiac injury syndrome (Dressler’s syndrome) 1584
tuberculous pleural effusion 1571
F
Fabric manufacturing 1529
Factors for asthma mortality 917
Familial predisposition to lung cancer 1308
Fat embolism 1213
Fiberoptic bronchoscopy 287, 1402
Fibrocartilaginous layer 52
Fibrosing mediastinitis 1645
Fibrosis 153
Five-flucytosine 835
Flail chest 1180
Fluconazole 273
Flucytosine 835
Fluoroquinolone compounds 539
Fluoroquinolones 264
Fluoroscopy 137
Food allergen 873
Forced expiratory spirogram 75
Forced expiratory volume 75
Forced inspiratory flow 76
Forced vital capacity 75
Fungus ball 816
G
Gallium-67 lung scanning 190
Ganciclovir 275
Gas dilution method 68
Gas exchange 1234
Gas transport in blood 84
Gastroesophageal reflux 879
Gastroesophageal reflux and asthma 981
Gastroesophageal reflux disease 1028
Gastrointestinal symptoms 718
Gatifloxacin 583
Gene therapy and future strategies 450
General principles of approach to treatment of chronic persistent asthma 955
alternative and complementary therapies 959
assessment of asthma control 960
Genetic probes 520
Genetics 1250
Genetics and asthma 881
Genomic structure of M. tuberculosis 481
Gentamicin 263
Giddiness 718
Gina guidelines 1009
Glanders 377
Global TB epidemic 465
Global tuberculosis–2008 474
incidence 475
estimated incidence of MDR-TB 475
extensively drug resistant tuberculosis 477
incidence of TB among people infected with HIV 475
targets and strategies for TB control 475
Glucocorticosteroids 1135
Glus syndrome 1393
Government commitment and coordination 694
coordination 695
general considerations 694
objectives 694
political commitment 694
regulatory and operational documents 694
sufficient economic support 694
political commitment 695
summary and check list 695
Government health facilities outside state health departments 618
corporate sector 618
management of TB cases presenting to hospital as outdoor patients 619
medical colleges 619
nongovernmental organizations 618
private providers 618
Gram stain 283
Gramicidin 261
Gram-negative pneumonias 340
Granulomatous lesions 1393
Gross anatomy of thorax 60
Guidelines for use of pediatric patient wise boxes under revised national tuberculosis control programme 1727
categorization and duration of therapy 1729
chemoprophylaxis 1729
use of prolongation pouches 1729
H
Hamman-Rich syndrome 1255
Hand hygiene 1781
Health education 1742
Heightened ventilatory demand 26
Heliox 1001
Helium-oxygen mixture 1176
Hematological and biochemical investigation 1334
Hematological changes and oxygen transport 99
Hemodynamic consequences of cor pulmonale 1188
left ventricle in cor pulmonale 1189
Hemodynamic monitoring 1234
Hemophilus influenzae pneumonia 343
clinical features 344
diagnosis 344
pathogenesis 344
treatment 345
Hemoptysis 10, 507
diagnostic approach 11
management 12
Hepatic hydrothorax 1570
nephrotic syndrome 1571
Hepatitis 719
Hereditary abnormalities 432
Herpes simplex virus pneumonias 391
Heterologous prime/boost combinations 576
High altitude cerebral edema 100
High altitude pulmonary edema 100
High resolution CT scanning 1257
Histamine 891
Histiocytosis X 1277
Histological classification of lung cancer 1309
Histoplasmosis 824
clinical features 825
treatment 826
History of tuberculosis 455
characteristics of patients in world 457
current status of global burden of tuberculosis 465
epidemiology 456
epidemiology of tuberculosis in India 463
estimating TB incidence, prevalence and death rates 466
global TB epidemic 465
HIV infection and tuberculosis in India 464
results 468
case notifications and incidence estimates 468
monitoring progress in TB control countries reporting to WHO 468
surveillance and epidemiology 471
achievements 472, 473, 474
address TB/HIV, MDR-TB and other challenges 472
budget and finance, 2007 471
challenges 472, 473, 474
collaborative TB/HIV activities, 2005 471
engage all care providers 473
laboratory services, 2005 g 471
management of MDR-TB, 2005 471
planned activities 472, 473, 474
pursue high-quality DOTS expansion and enhancement 472
surveillance and DOTS implementation, 2005 471
HIV and tuberculosis 1714
prevention 1719
treatment 1718
HIV infection and AIDS 559
HIV infection and tuberculosis 559
in absence of HIV testing 559
HIV infection and tuberculosis in India 464
Home management 1140
Homogenization 705
Hospital acquired pneumonia 1782
empiric antibiotic therapy 1783
Hospital admission for asthma within last year 919
Hospital discharge and follow-up 1002
Hospital discharge and future plan of action 973
Hospital management 1140
Hospital waste management 620
Hospitalization 600
Human metapneumovirus 396
Human resource development for DOTS-plus under RNTCP 723
challenges for RNTCP in reaching goal 724
challenges in HRD for DOTS-plus 723
framework for HRD 723
general considerations 723
long-term goal for HRD for DOTS-plus 724
objectives 723
system for HRD for DOTS-plus 724
Human resources required for DOTS-plus at NRLS and IRLS 704
Humidity 85
Humoral immunity within lung 130
Hyaline membrane disease 1761
clinical features 1763
criteria of admission into an ICU 1770
management 1763
pathology 1763
surfactant therapy 1764
Hydatid disease 859
clinical features 859
diagnosis 859
treatment 859
Hypersensitivity pneumonitis 1278
Hypertrophic pulmonary osteoarthropathy 2
Hyperventilation 107
Hypoplasia of lung 1678
Hypothermia after cardiac arrest 1778
Hypothyroidism 719
Hypoxemic respiratory failure 1176
Hypoxia 1187
Hypoxia response curves 97
I
Identification tests 707
Idiopathic kyphoscoliosis 1657
Idiopathic pulmonary fibrosis 1249
definition 1249
environmental factors 1250
epidemiology 1249
genetics 1250
infections 1250
risk factors for IPF 1249
smoking 1250
Imipenem premaxin 259
Immunity in tuberculosis 487
clinical features of tuberculosis 495
congenital tuberculosis 495
extrapulmonary tuberculosis 503
miliary tuberculosis 497
pathology 490
postprimary tuberculosis 498
primary tuberculosis 496
radiographic features 500
Immunocompromised host 311
Immunodeficiency states 431
Immunodiagnosis of tuberculosis 521
Immunoglobulin isotypes 129
Immunoglobulins 122
Immunological lung diseases 131
evaluation of immune functions of lung 132
type 131
Immunological management 950
Immunological markers 1567
Immunological mechanisms 119
activation of T tymphocytes 120
antigen presenting cells 120
antigen reacting cells 120
cell-mediated cytotoxicity 121
effector B cells 121
function of immunoglobulins 122
immune response in lung parenchyma 123
immune responses in the bronchial mucosa 122
regulation of pulmonary immune responses 123
structural basis of pulmonary immune response 121
uptake of antigen and immune defence in lungs 121
Immunologically mediated pleural effusions 1581
Immunology and pathogenesis of sarcoidosis 1390
pathology 1392
granulomatous lesions of unknown significance 1393
tumor-related sarcoid reactions 1393
T cell receptor 1391
Immunomodulators 1136
Immunopathological march in sarcoidosis 1394
Immunoregulators 1136
Immunostimulators 1136
Immunosuppressive therapy for lung transplantation 1692
infection 1695
rejection 1693
Immunosupressants 1269
Immunotherapy 952
pharmacological therapy 952
Immunotherapy and primary prevention 986
Implementation of COPD guidelines 1145
Incubation 706
Indian patients with cystic fibrosis 448
diagnosis 448
gene therapy and future strategies 450
newborn screening 448
treatment 448
Indications of lung transplantation 1689
Indications of thoracoscopy 219
pleural effusion of unknown etiology 219
bullectomy/LVRS 221
chest trauma 221
chylothorax 220
empyema 220
malignant pleural effusions 220
mesothelioma 219
pulmonary diseases 220
recurrent pleural effusion of benign etiology 220
spontaneous pneumothorax 220
tubercular pleural effusion 219
Indoor allergens 950
Indoor and outdoor air pollution 1132
Inert gas narcosis 103
Infection control and hospital waste management 620
types of wastes generated by RNTCP 621
disposal of sputum container with specimen and wooden sticks 621
disposal of used slides 622
disposal of used syringes/needles/broken vials 621
under no circumstances should slides be broken or recycled 622
Infection control practices 1781
active surveillance 1782
hand hygiene 1781
Infectious croup 1704
Inflammation and cytokines in asthma 892
Inflammatory bowel disease 433
Inflammatory cells in asthma 884
basophils 888
eosinophils 885
epithelial cells and adhesion molecules 888
lymphocytes 886
mast cells 884
monocytes and macrophages 887
neutrophils 888
Inflammatory mediators in asthma 889
bradykinin 891
cytokines 891
inflammation and cytokines in asthma 892
histamine 891
leukotrienes 889
mast cell proteases 891
neurotrophins 895
nitric oxide 894
oxygen radicals 894
platelet-activating factor 891
prostaglandins 891
Influenza pneumonia 383
clinical manifestations 386
diagnosis 388
epidemiology 383
pathophysiology 385
prevention 389
treatment 388
Information system 728
Information, education and communication 622
communication channels, activities and materials 622
interpersonal channels 622
mass media 623
nonelectronic and outdoor media 623
functions medical college core committee 637
functions of CTD 624
functions of intermediate reference laboratory 636
functions of national task force 637
functions of state task force 637
functions of state TB cell 625
functions of state TB training and demonstration centre 626
functions of zonal task force 637
key functions of tuberculosis unit team 630
monitoring of IEC in RNTCP 623
objectives of IEC under RNTCP 622
responsibilities of medical officer-tuberculosis control 630
responsibilities of multipurpose health supervisors/lady health visitor/ health assistant 634
responsibilities of state accountant 627
responsibilities of data entry operator 629
responsibilities of DTO 628
responsibilities of laboratory technician/microscopist or trained laboratory assistant 633
responsibilities of the medical officer of DTC 628
responsibilities of microbiologist 636
responsibilities of multipurpose health worker/TB health visitor 633
responsibilities of pharmacist 635
responsibilities of senior TB laboratory supervisor 631
responsibilities of senior treatment supervisor 630
responsibilities of state IEC 627
responsibilities of statistical assistant 628
responsibilities of the treatment organizer (wherever available) 628
roles and responsibilities for IEC activities at center, state and district 623
role of center in IEC 623
role of district in IEC 623
role of the state in IEC 623
roles of STO/DTO in strengthening involvement of medical college hospitals in RNTCP 638
roles of the deans/directors of medical college hospitals in RNTCP 638
target audience 622
Inhalant anesthetics 972
Inhalation anthrax 339
Inhalation injuries 1542
chemical injuries 1545
ammonia 1545
chlorine 1546
nitrogen dioxide 1547
clinical presentation 1547
aspiration syndromes 1548
isocyanates 1548
TDI 1548
toxic fluids 1549
clinical management 1544
smoke inhalation 1543
carbon monoxide (CO) 1544
thermal injury 1543
toxic gases and particulate matter 1543
Inhalation therapy 944
dry powder inhalers 945
nebulizers 945
pressurized aerosol systems 944
Inhaled steroids 991, 1004
Innate immune cells 125
Inoculation 706
Inspired partial pressure of oxygen (PiO2) 85
Intensive insulin therapy in critically ill patients 1778
Interleukin-12 and interleukin-18 in t1 differentiation 125
Intermediate reference laboratories 636, 747
International Association for Study of Lung cancer (IASLC) prospective lung cancer staging project 1319
International standards of tuberculosis care (ISTC) 763
standards for diagnosis 764
standards for public health responsibilities 765
standards for treatment 764
Interstitial disease 153
Interstitial fibrosis 1448
Interstitial lung disease 215, 1440
Intracellular oxygen tension 85
Intrathoracic lesions 197
Intrathoracic sarcoidosis 1394
Intrauterine exposure 1734
Intravenous aminophylline 1000
Intravenous fluids 1001
Intravenous magnesium sulphate 1000
Intravenous salbutamol 1003
Intrinsic and extrinsic asthma 907
Intubation 971
Intubation-endotracheal 1774
laryngoscope 1774
Invasive mechanical ventilation 1142
Invasive procedures 285
fiberoptic bronchoscopy 287
thoracentesis 287
transtracheal needle aspiration 285, 286
Invasive pulmonary aspergillosis 820
clinical features 821
diagnosis 821
pathology 821
treatment 822
Invasive ventilation 1176
Iposomal amphotericin B 271
Ipratropium bromide 1000
Iron and lungs 1540
Irritants or chemicals 1741
Isocyanates 1548
Isoflow 78
Isoniazid 531
Itraconazole 273
J
Job responsibilities for various categories of staff under DOTS-plus 748
Joint tuberculosis programme review, India 2006 757
challenges 757
executive summary 757
achievements 757
key recommendations 758
address long-term financial and human resource sustainability of program 758
further develop and implement strategies for MDR-TB and TB-HIV 759
improve program effectiveness 759
Jugular venous pressure 1
K
Kanamycin and neomycin 263, 539, 717
Kaolin lung 1539
Ketoconazole 272
Ketotifen 940
Klebsiella pneumonia 345
clinical features 347
diagnosis 348
pathogenesis 346
pathology 347
treatment 349
Kveim-Siltzbach test 1402
Kyphoscoliosis 1656, 1658
ankylosing spondylitis 1660
clinical features 1658
etiology 1661
Costochondritis (Tietze’s syndrome) 1663
tumors of chest wall 1663
flail chest 1661
idiopathic 1657
medical management 1658
objective assessment of pectus disorders 1659
pectus carinatum 1659
pectus excavatum or funnel chest 1659
physiological changes associated with kyphoscoliosis 1657
rib abnormalities 1660
L
Laboratory and serological tests 1265
Laboratory aspects 703
accreditation of IRLS for culture and DST under RNTCP 708
culture examination and identification 706
examination schedule 706
reading of cultures 706
culture of sputum specimens 704
digestion and decontamination procedures 705
processing of sputum specimens containing CPC and NACL 705
drug susceptibility tests 707
criteria of resistance 708
DST methods 707
general considerations 703
homogenization and decontamination 705
identification tests 707
inoculation and incubation 706
objectives 703
organization and development of laboratory network 703
human resources required for DOTS-plus: at NRLS and IRLS 704
job responsibilities under DOTS-plus 703
quality assurance programme 708
proficiency testing 708
recording and reporting of laboratory results 706
Laboratory diagnosis of NTM 795
Large cell carcinoma 1314
Laryngoscope 1774
Larynx 47
Late asthmatic reaction 883
Late onset asthma 907
Lateral decubitus films 136
Left ventricle in cor pulmonale 1189
Legionellosis (Legionnaires’ disease, pontiac fever) 361
clinical features 363
course and complications 365
diagnosis 364
epidemiology 362
microbiology 361
pathogenesis and pathology 362
radiology 364
treatment 364
Legionnaires’ disease 361
Leukotriene antagonists and synthesis inhibitors 941
Leukotriene receptor antagonists 1001
Leukotrienes 889
Lifestyle modifications 1026
Life-threatening acute asthma exacerbations 919
Lincomycin 267
Linezolid 269
Lipid studies 1567
Live vectors 576
Liver disease 548
Local detoxification 115
Logistics of second-line anti-TB drugs 725
objectives 725
Long-term outcome of ARDS 1240
Lower respiratory tract infections 1705
bronchiolitis 1705
pneumonias 1706
prevention of ARI 1708
viral infections 1707
bacterial pneumonias 1707
mixed pneumonia 1708
supportive therapy in ARI 1708
WHO protocol for ARI management 1708
Lung 70
Lung abscess 507
Lung biopsy 222, 277, 278 1265
open lung biopsy 225
percutaneous transthoracic needle aspiration (PTNA) 224
transbronchial biopsy 223
transbronchial needle aspiration 223
Lung cancer 183, 1307
Lung cancer in India 1302
Lung cancer in World 1297
Lung capacities 68
Lung compliance 73
lung defense 116
Lung function tests 98, 1530
Lung injury 1227, 1234
Lung parenchyma 123
Lung reactions to inhaled particles 1463
Lung receptors 95
Lung scans 1203
Lung sounds 6
Lung transplantation 1138, 1689, 1273, 1404
Lung volume reduction surgery 1138
Lung volumes and capacities 68
Lupus pneumonitis 1446
Lymph nodes 59
Lymphadenitis 606, 793
Lymphadenopathy 1
Lymphangioleiomyomatosis 1378
Lymphangiomas 1644
Lymphatic drainage of the lungs 58
Lymphatics 1586
Lymphocytes 886
Lymphomas 1374
Lymphomatoid granulomatosis 1429
M
M. avium complex disease 797, 798
M. kansasii 795
disseminated M. avium complex disease 797
prophylaxis for disseminated M. avium complex disease in AIDS 798
pulmonary M. avium complex disease (M. avium, M. intracellulare) 796
rapidly growing mycobacteria 798
M. marinum 798
M. Marinum 798
Macrolide and azalide antibiotics 266
side effects 267
Macrophages 55, 486
Magnetic resonance imaging 1332
Maintenance therapy 1022
Malaria 842
Malignant mesothelioma 1506
asbestos 1507
biopsy 1510
chemotherapy 1514
clinical features 1509
etiopathogenesis 1507
genetic 1508
palliative care 1516
prevention of asbestos-related diseases 1517
prognostic factors in mesothelioma 1516
pathology 1509
radiation 1514
surgery 1512
treatment 1512
virus 1508
Malignant mesothelioma 1580
Malignant pleural effusions 220
Malignant tumors of nerve sheath origin 1641
Management of allergy 921
Management of asthma in children 1739
classification of asthma severity 1740
environmental control and prevention of asthma 1741
allergen avoidance 1741
irritants or chemicals 1741
psychosocial aspects of asthma management in children 1742
future directions for research 174
goals of asthma therapy 1740
health education 1742
measures of assessment and monitoring 1739
pharmacological therapy 1740
referral 1740
Management of asthma with special problems 973
Management of bronchial asthma 920
Management of COPD 1127
initial diagnosis 1128
Management of extra-pulmonary tuberculosis 605
management of pleural TB 606
management of TB lymphadenitis 605
diagnostic algorithm for TB lymphadenitis 606
Management of nonsevere exacerbations 1023
Management of patients with HIV infection and tuberculosis 606
antituberculosis therapy and antiretroviral therapy 607
DOTS in TB-HIV 607
operationalization of VCTC-RNTCP cross-referral linkages (VCTC now called ICTC) 607
steps for operationalization 607
referral of persons from VCTC to RNTCP 608
at designated microscopy center 608
at VCTC 608
referral of TB patients to VCTC for HIV-testing 608
Management of pediatric tuberculosis under RNTCP 604
chemoprophylaxis 605
diagnosis 604
RNTCP treatment categories and regimens for children 604
role of BCG vaccination 605
treatment of pediatric TB 604
Management of severe exacerbations 1023
Mantoux test 1403
Mass media 623
Massive pulmonary embolism 1200
Mast cell proteases 891
Mast cells 884
Maximum breathing capacity 75
Maximum expiratory flow volume curve 76
maximum voluntary ventilation 75
MDR-TB 553
causes 554
MDR-TB in special situations 713
management of contacts of MDR-TB 716
MDR-TB in patients with pre-existing liver disease 715
MDR-TB in patients with psychosis 716
MDR-TB in patients with renal impairment 715
MDR-TB in patients with seizure disorders 715
MDR-TB in pregnancy 713
MDR-TB requiring surgery 714
MDR-TB with co-infected HIV infection 714
objectives 713
Measurement of ventilatory drive 96
carbon dioxide response curves 96
hypoxia response curves 97
resting PaCO2 96
Mechanical earners 115
Mechanical ventilation 67, 971, 1174, 1235
bronchoalveolar lavage 973
inhalant anesthetics 972
intubation 971
mechanical ventilation 972
noninvasive ventilation 971
paralysis 971
sedation 971
Mediastinal and hilar shadows 162
Mediastinal cysts 1642
bronchogenic cysts 1643
enterogenous cysts 1643
lymphangiomas 1644
neuroenteric cysts 1643
pericardial cysts 1643
Mediastinal fibrosis 1645
Mediastinal germ cell tumors 1637
mediastinal teratomas 1638
mediastinal nonseminomatous GCTS 1639
mediastinal seminoma 1639
Mediastinal goiter 1644
Mediastinal nonseminomatous GCTS 1639
Mediastinal pain 23
Mediastinal parathyroid adenoma 1645
Mediastinal seminoma 1639
Mediastinal teratomas 1638
Mediastinal tumors/cysts 1625, 1627
diagnostic approach to mediastinal tumors 1627
symptoms and signs 1626
Mediastinitis 1645
Mediastinoscopy 222, 260 1332
Mediastinum 1644
Medical College Core Committee 637
Medical thoracoscopy 221
Medication use 919
complications of bronchial asthma 920
Medullary respiratory center 94
Melioidosis 376
Membrane-active agents 261
Meropenem 259
Mesothelioma 219, 1516
Metabolic acidosis 92
Metabolic alkalosis 93
Metabolic function 81
Metabolism 66
Metastasis 152
Metastatic tumors in the lung 1378
Metered dose inhalers 944
Methacycline 266
Methicillin resistant—Staphylococcus aureus 334
Methylxanthines 923
adenosine receptor antagonism 924
anti-inflammatory effect 924
effect on respiratory muscles 924
increased catecholamine release 924
inhibition of calcium ion flux and other extrapulmonary effects 924
phosphodiesterase inhibition 924
side effects 926
Metronidazole 268
Miconazole 272
Microbes 439
Microbial exposure 986
Microbiology and virulence factors 361, 373
Microscopic polyangiitis 1430
Microvascular maturation 45
Mild asthma 1020
moderate asthma 1022
reduction of maintenance therapy 1022
severe asthma 1022
Miliary tuberculosis 497
Mineral pneumoconioses 1526
Mineralogic analysis 1470
Minocycline 266
Minute ventilation 65
Miscellaneous antibiotics 267
chloramphenicol 268
clindamycin and lincomycin 267
metronidazole 268
sulfonamides 268
adverse effects 269
clinical uses 269
Miscellaneous disorders of mediastinum 1644
chest wall and thoracic cage abnormalities 1656
clinical features 1646
computed tomography 1647
investigations232 1647
chest radiography 1647
MR imaging 1648
primary mediastinal lymphoma 1644
mediastinal fibrosis (fibrosing mediastinitis) 1645
mediastinal goiter 1644
mediastinal parathyroid adenoma 1645
mediastinitis 1645
treatment 1649
Miscellaneous pneumonias 372
Miscellaneous procedures 225
endobronchial ultrasound 225
endoscopic ultrasound 225
Miscellaneous viral pneumonias 396
Mixed connective tissue disease 1458
Moderate asthma 1022
Modified infant milk formulae 986
Molecular basis of lung development 43
alveolar period 45
canalicular period 44
embryonic period 43
microvascular maturation 45
pseudoglandular period 43
saccular period 44
Molecular basis of drug resistance 556
Molecular methods 524
Mometasone 994
Monge’s disease 102
Monitoring and management of adverse drug reactions 717
adverse effects, suspected drugs and management strategies 718
arthralgia 718
cutaneous reactions 718
gastrointestinal symptoms 718
giddiness 718
hepatitis 719
hypothyroidism 719
neurological symptoms 719
ocular toxicity 718
psychiatric disturbances 719
renal toxicity 718
vestibulo-auditory disturbances 719
common adverse reactions to drugs used 717
aminoglycosides—kanamycin and amikacin 717
cycloserine 718
ethambutol 717
ethionamide 717
pas 718
pyrazinamide 717
quinalones/ofloxacin 717
monitoring for early detection of adverse reactions 717
objective 717
role of DOTS-plus committee in the management of adverse reactions 719
Monobactam 258
Monocytes and macrophages 887
Morgagni hernia 1665
Morning dippers 909
Morphology of respiratory tract 46
alveoli 53
alveolar epithelium 53
endothelium 54
macrophages 55
surfactant 54
blood vessels of lung 56
bronchial circulation 56
pulmonary circulation 57
bronchi 48
bronchial histology 50
fibrocartilaginous layer 52
mucosa 50
submucosa 52
larynx 47
lymph nodes 59
anterior mediastinal nodes 59
posterior mediastinal nodes 59
tracheobronchial nodes 59
lymphatic drainage of lungs 58
nasal airway 46
nerves of lungs 60
pharynx 47
terminal respiratory unit 53
trachea 48
Morphometric videobronchoscopy 1677
Mortality 867
Mounier-Kuhn syndrome 1674
Moxalactam 258
Moxifloxacin 580
Mucociliary clearance 112
Mucoepidermoid tumor 1375
Mucormycosis 831
Mucosa 50
Mucosal vaccination 576
Mucus 112
Multi-drug resistance tuberculosis in India 475, 555
clinical features and diagnosis of MDR-TB 556
molecular basis of drug resistance 556
treatment of MDR-TB 557
Multi-drug resistant tuberculosis and DOTS plus 619
drug resistance surveillance 620
extent of MDR TB in India 620
management of MDR-TB 620
prevention of MDR-TB 620
Muscles of respiration 69
Mycetoma 816
Mycetoma and HIV-infection 819
Mycobacteria 518
Mycobacteriophage typing 522
Mycoplasma pneumoniae pneumonia 366
clinical features 367
diagnosis 368
epidemiology and pathogenesis 367
treatment 369
N
Narcotics (morphine) 1136
Nasal airway 46
Nasal polyps 1027
National DOTS-plus committee 747
National reference laboratories 636, 747
National review of program 614
National task force 637
Natural history and hemodynamic consequences 1199
acute unexplained dyspnea 1201
massive pulmonary embolism/acute cor pulmonale 1200
pulmonary infarction 1199
Natural history of bronchial asthma 869
Natural history of COPD 1080
clinical features of COPD 1087
differential diagnosis 1092
management 1094
mechanisms of airway obstruction in COPD 1082
pathogenesis 1081
pathology 1085
physical signs 1087
prevention measures 1094
prognosis 1093
respiratory airspace enlargement 1086
staging of COPD 1093
symptoms 1087
Naturally occurring plague 372
Nebulizers 945
Necrobiotic nodules 1441
Necrotizing sarcoidal granulomatosis 1430
Nedocromil sodium 939, 940
Needles 621
Negative pressure ventilation 1175
Nematodal parasites 846
treatment 847
Nephrotic syndrome 1571
Nerve sheath tumors 1641
Neuroenteric cysts 1643
Neurogenic tumors 1640
autonomic ganglionic tumors 1641
malignant tumors of nerve sheath origin 1641
nerve sheath tumors 1641
Neurological symptoms 719
Neuropeptides in asthma 895
beta-adrenergic receptors and asthma 898
bronchial hyperreactivity 896
nitric oxide and bronchial asthma 898
Neurotrophins 895
Neutrophils 118, 888, 1227
New anti-TB drugs 579
diarylquinoline TMC 583
gatifloxacin 583
miscellaneous drugs 584
moxifloxacin 580
New guidelines 985
nonpharmacological management 986
primary prophylaxis 986
allergen avoidance 986
breastfeeding 986
immunotherapy and primary prevention 986
microbial exposure 986
modified infant milk formulae 986
pharmacotherapy 987
secondary prophylaxis 987
allergen avoidance 987
complementary and alternative medicine 988
dietary manipulation 989
environmental factors 988
weight reduction in obese patients with asthma 989
New treatment modalities/newer drugs for bronchial asthma 982
anti-immunoglobulin E antibodies 982
anti-interleukin-5 antibodies 984
PDE4 inhibitors 984
soluble interleukin-4 receptors 983
New tuberculosis vaccines 574
Newborn screening 448
Newer antitubercular drugs 533 539
fluoroquinolone compounds 539
macrolides 540
rifamycin derivatives 540
Newer lipid formulations 835
Newer modes of ventilation 1236
Newer strategies for lung cancer treatment 1349
Newer technologies 520
Newer vaccines 574
attenuated mycobacteria 575
heterologous prime/boost combinations 576
immunotherapy 576
live vectors 576
mucosal vaccination 576
vaccination approaches 575
Nickel and lungs 1536
Nitric oxide 894
Nitric oxide and bronchial asthma 898
Nitrogen dioxide 1547
Nocardiosis 833
Noctural asthma 904
Noncardiac thoracic surgery 229
Nonelectronic and outdoor media 623
Nongovernmental organizations 618
Noninvasive mechanical ventilation 1142
Noninvasive positive pressure ventilation 1174
acute exacerbation of chronic respiratory failure 1175
cardiogenic pulmonary edema 1176
continuous positive airway pressure 1176
helium-oxygen mixture 1176
hypoxemic respiratory failure 1176
negative pressure ventilation 1175
Noninvasive procedures 283
blood culture 285
detection of antigen 285
expectorated sputum 283
Gram stain 283
nucleic acid detection 285
serology 285
sputum culture 284
Noninvasive ventilation 971
Nonpharmacologic management 920
Nonpharmacologic treatments 1137
oxygen therapy 1137
rehabilitation 1137
ventilatory support 1137
Nonpharmacological management 986
Nonresolving pneumonia 419
clinical features 422
congenital anatomic defects 431
cystic fibrosis 433
diagnosis 423
differential diagnosis 425
hereditary abnormalities 432
immunodeficiency states 431
infection 429
inflammatory bowel disease 433
obstruction 431
pathogenesis 421
pathology 422
predisposing conditions 429
rheumatoid arthritis 433
treatment 425
Nonsevere exacerbations 1023
Nonsmall cell lung cancer 1340
chemotherapy 1343
radiotherapy 1342
surgery 1340
treatment schedules 1342
Nonspecific constitutional manifestations 1394
Nonspecific defense mechanisms 116
Nonspecific interstitial pneumonia 1255
Nonspecific mechanisms 111
Nonthoracic surgery 229
Nonthrombotic pulmonary embolism 1213
fat embolism 1213
Normal beta-adrenergic receptor physiology 927
Nosocomial pneumonia 298, 301
clinical features 301
etiology 299
pathogenesis 300
prognosis and prevention 304
treatment 303
Novel therapeutic approaches 1271
Novel therapies 994
adverse psychosocial and behavioral factors 995
anti-IGE monoclonal antibody 994
disease factors 994
management of acute asthma 994
medical management 994
mometasone 994
tiotropium bromide 994
Nucleic acid detection 285
O
Obstructive sleep apnea 104
Obstructive ventilatory defect 195
Occupation and asthma 876, 903, 915
Occupational lung diseases peculiar to India 216, 1552
preventive measures for occupational diseases 1553
Occupational risks 1306
Ocular toxicity 718
Ofloxacin 717
Older patients with asthma 979
Oncogenes and lung cancer 1308
Ondine’s curse 109
Ontogeny of GD T cells 126
Open lung biopsy 225
Open negative syndrome 511
Open pleural biopsy 1569
Oral anticoagulant therapy 1210
Oral contraceptive pills 601
Oral steroid dependence 942
Ornithosis 371
Other characteristics of pleural fluid 1564
biochemical measurements 1566
cellular contents 1564
diagnosis of pleural malignancy 1568
fiberoptic bronchoscopy 1569
immunological markers 1567
lipid studies 1567
open pleural biopsy 1569
physical appearance 1564
thoracoscopy 1569
Other diseases 1460
fate of inhaled particles 1462
lung reactions to inhaled particles 1463
Other host factors and lung cancer 1307
Other mineral pneumoconioses 1526
Other nonspecific defense mechanisms 116
altered functions 119
antioxidant systems 116
airway submucosa 117
apoptosis and lung defense 116
macrophages and neutrophils 118
stress proteins 117
surfactant and defense 118
Other novel therapeutic approaches 1271
Other NTM infections 798
diseases caused by phagocyte opportunists 805
diseases caused by T cell opportunists 805
Other pneumoconioses 1533
aluminium and lungs 1541
baritosis 1541
chromium related lung diseases 1536
chronic beryllium disease (CBD)/ berylliosis 1533
iron and the lungs 1540
Kaolin lung 1539
mechanism of action 1538
nickel and the lungs 1536
prevention 1534
rare metal related lung diseases 1542
talc worker’s pneumoconiosis 1539
treatment 1534
Welder’s lung 1537
Other related problems of ventilatory management 1237
Other supportive measures in ICU 1778
ARDS management 1780
blood transfusions 1779
early goal-directed therapy in severe sepsis and septic shock 1780
induced hypothermia after cardiac arrest 1778
intensive insulin therapy in critically ill patients 1778
noninvasive mechanical ventilation 1778
other interventions in severe sepsis 1779
problems of critical care 1781
selective decontamination of digestive tract 1780
steroids in septic shock 1779
vasopressin administration in septic shock 1780
Outdoor allergens 950
Oxazolidinones 269
linezolid 269
Oxygen administration 1772
Oxygen radicals 894
Oxygen therapy 1137, 1141, 1173
Oxygen toxicity 103
Oxygen transport 84
Oxyhemoglobin dissociation curve 86
Oxytetracycline 266
P
Palliative care 1516
Palpation 4
Pancoast’s syndrome 1344
Para-aminosalicylic acid 537
side effects 537
Paracoccidioidomycosis 829
clinical features 829
diagnosis 830
treatment 830
Paragonimiasis 861
clinical features 862
treatment 862
Parainfluenza virus pneumonia 383
Paralysis 971
Paralytic kyphoscoliosis 1657
Parapneumonic effusions 1575
Parasites 409
Parasitic pleural effusions 1576
Parenchymal atelectasis 146
Pas 718
Passive smoking 1077
Pathogenesis and biology of lung cancer 1314
Pathogenesis of bronchiectasis 433
acute exacerbations or bronchitis 439
bronchopulmonary hygiene 440
clinical features 435
complications 438
investigations 93, 94, 436
management 439
pathology 434
prevention or suppression of microbes 439
bacteriology of bronchiectasis 439
prognosis 441
surgery 440
Pathogenesis of respiratory tract infections 280
Pathophysiology of bronchial asthma 882
early asthmatic reaction 882
late asthmatic reaction and bronchial hyperreactivity 883
Patient and family counseling 712
Patient and family education 920
Patient assessment 1163
Patient education 948, 1026
Patient referral 1024
Patterns of airflow obstruction in chronic asthma 909
Brittle asthma 909
bronchoprovocation test 913
COPD and bronchial asthma 915
laboratory studies 911
morning dippers 909
objective tests 912
sign of asthma 910
symptoms of asthma 910
Peak expiratory flow rate 76
Pectus carinatum 1659
Pectus disorders 1659
Pectus excavatum or funnel chest 1659
Pediatric tuberculosis under RNTCP 604
Penicillins 253
Percussion 5
Percutaneous transthoracic needle aspiration 224
Perfusion (Q) 79
distribution of blood flow 80
function of the pulmonary circulation 81
metabolic function 81
water balance 81
ventilation 82
Pericardial cysts 1643
Peripheral airway disease 1072
Peripheral chemoreceptors 94
Peripheral health institutions 589
PET scans 1333
Phagocyte opportunists 805
Phagocytosis 115
Pharmacologic management of asthma 923
Pharmacologic therapy 1095
bronchodilators 1095
Pharmacologic treatments 1136
Pharmacological management 989, 1238
combination inhalers 992
comparison of inhaled steroids 991
criteria for introduction of add-on therapy 991
frequency of dosing of inhaled steroids 990
safety of inhaled steroids 990
starting dose of inhaled steroids 990
Pharmacotherapy 1131
antioxidant agents 1136
antitussives 1136
bronchodilators 1134
education 1133
glucocorticosteroids 1135
immunoregulators (immunostimulators, immunomodulators) 1136
indoor and outdoor air pollution 1132
mucolytic (mucokinetic, mucoregulator) agents (ambroxol, erdosteine, carbocysteine, iodinated glycerol) 1136
narcotics (morphine) 1136
occupational exposures 1132
antibiotics 1136
vaccines 1136
pharmacologic treatments 1133
vasodilators 1136
Pharynx 47
Phosphodiesterase inhibition 924
Physiological considerations of pleural space 1558
Pickwickian syndrome 109
Plague 372
diagnosis 373
epidemiology 372
naturally occurring plague 372
plague following use of a biological weapon 373
infection control 374
microbiology and virulence factors 373
pathogenesis and clinical manifestations 373
postexposure prophylaxis recommendations 374
treatment 374
vaccination 374
Platelet-activating factor 891
Pleural disease 1501
pleural effusion 1500, 1559
Pleural malignancy 1568
Pleural plaques 1497
Pleuropulmonary 23
Pleuropulmonary amebiasis 409
Pneumococcal pneumonia 323
clinical features 325
complications 326
diagnosis 327
drug resistance to S. pneumoniae 328
epidemiology 323
laboratory and roentgenographic findings 326
microbiology 323
pathogenesis 324
pathology 325
prophylaxis 329
treatment 327
Pneumoconioses 1463, 1533
Pneumocystis jirovecii pneumonia 411
clinical features 413
diagnosis 413
epidemiology 411
pathogenesis 412
prognosis 414
treatment 413
Pneumonia 279, 507
Pneumonia in the immunocompromised host 311
diagnosis of pulmonary infections in immunocompromised hosts 313
pathogenesis 311
treatment of pneumonia in immunocompromised patients 314
Pneumonias due to parasites 409
Pneumonias due to specific agents 323
Pneumotaxic center 94
Pneumothorax 1596
active management 1601
classification and etiology 1596
clinical features 1599
conservative approach 1601
management 1601
primary spontaneous pneumothorax 1596
secondary spontaneous pneumothorax 1598
traumatic pneumothorax 1598
Poisoning 1180
Pollutants 987
Pollution 880
Polyarteritis nodosa 1427
bronchocentric granulomatosis 1429
clinical features 1427
histology 1428
imaging 1428
lymphomatoid granulomatosis 1429
microscopic polyangiitis 1430
necrotizing sarcoidal granulomatosis 1430
Polymixin B 261
Polymyositis-dermatomyositis 1459
Pontiac fever 361
Positional dyspnea 27
Positron emission tomography scan 183
Postcardiac injury syndrome 1584
Posterior mediastinal nodes 59
Postexposure prophylaxis recommendations 374
Postoperative analgesia 229
Postoperative factors 228
Postoperative management 1692
Postoperative measures 229
Postoperative pulmonary complication 227
Postprimary tuberculosis 498
Post-traumatic respiratory failure 1180
Potential hazards of oxygen therapy 1173
Pouches 756
Prediction and prevention of a severe asthma attack 997
Pre-existing liver disease 715
Pregnancy and asthma 976
Prenatal development 39
airways 39
alveoli 40
blood vessels 41
connective tissue 40
Preoperative evaluation of pulmonary function tests 226
Preoperative pulmonary assessment 228
noncardiac thoracic surgery 229
nonthoracic surgery 229
postoperative analgesia 229
preventive strategies for PPC 228
anesthetic measures 229
intraoperative measures 229
postoperative measures 229
preoperative measures 228
principles of antibiotic therapy 242
Preoperative risk factors 227
pressure support plus positive end-expiratory pressure 1176
Pressurized aerosol systems 944
Preventer therapies 991
Prevention and treatment of steroid tablet-induced side effects 993
B-blockers 993
specific management problems 993
exercise-induced asthma 994
onset of exacerbation asthma 993
stepping down 993
steroid formulations 993
steroid tablet-staring medication 993
Prevention of asthma 1024
primary prevention 1024
secondary prevention 1025
tertiary prevention 1025
Prevention of lung cancer 1345
Previous life-threatening acute asthma exacerbations 919
Primary drug resistance 552
Primary health care 763
Primary mediastinal lymphoma 1644
Primary prevention 1024
Primary prophylaxis 986
Primary spontaneous pneumothorax 1596
Primary tuberculosis 496
Principles of management 947
Proficiency testing 708
Prognosis of PTE 1215
Progressive systemic sclerosis 1452
interstitial lung disease 1452
lung cancer 1454
miscellaneous syndromes 1454
pulmonary hypertension 1453
Prolongation pouches 1729
Prostaglandins 891
Protective infections 1735
Proteus pneumonias 358
Pseudoglandular period 43
Pseudomonas aeruginosa pneumonia 355
Pseudotumors 1380
Psittacosis 371
Psittacosis (ornithosis) 371
treatment 372
Psychological and psychosocial problems 919
Public health responsibilities of health care providers 762
Public private mix (PPM) 618
Pulmonary abnormalities 1450
Pulmonary angiography 1204
Pulmonary arteriovenous malformation 1681
Pulmonary arteritis 1442
Pulmonary artery stenosis 1681
Pulmonary blastoma 1374
Pulmonary circulation 57, 81
Pulmonary complications of malaria 842
pathogenesis 843
Pulmonary disease 790, 1771
Pulmonary embolism 1449
Pulmonary function testing 190, 226, 1263
criteria of severity 196
mixed pattern 196
obstructive ventilatory defect 195
processing of results 193
restrictive defect 195
upper airway obstruction 196
extrathoracic lesions 197
intrathoracic lesions 197
Pulmonary hemorrhage 1447
Pulmonary hypertension 513, 1187, 1442
hypoxia 1187
other factors 1187
Pulmonary immune responses 123
Pulmonary infarction 507
Pulmonary infections in immunocompromised hosts 313
Pulmonary infections in SLE 1449
Pulmonary lymphoma 1457
Pulmonary M. avium complex disease (M. avium, M. intracellulare) 796
Pulmonary problems 1443
Pulmonary rehabilitation 1162
Pulmonary TB and HIV 562
Pulmonary tuberculosis 591
Pulmonary vagal receptors 26
Pulmonary vascular disease 1448
Pulmonary vasculature 1681
Pulse oximetry 1139
Pyrazinamide 535
side effects 535
Q
Q fever pneumonia 370
treatment 371
Quality assurance programme 708
Quinalones 717
R
Radiation 1514
Radiation pneumonitis 1282
Radiography 287
Radiology and imaging 134
abnormal radiological findings 142
airspace disease 146
parenchymal atelectasis 146
solitary pulmonary nodule 142
angiography 187
bronchography 186
chest skiagram 134
anteroposterior (AP) view 135
apicogram 136
expiratory skiagrams 136
fluoroscopy 137
lateral decubitus films 136
lateral view 135
oblique view 136
posteroanterior (PA) view 134
computed tomography (CT) 164
conventional tomography 162
fibrosis 153
gallium-67 lung scanning 190
interstitial disease 153
anatomic distribution 160
bullae or cyst 157
calcification 158
cavity 155
mediastinal and hilar shadows 162
miscellaneous radiological features 154
Silhouette sign 161
limitations of chest X-rays 142
magnetic resonance imaging 180
metastasis 152
positron emission tomography scan 183
lung cancer 183
radiotherapy planning 185
staging of lung cancer 184
reading a chest X-ray 137
normal X-ray 137
ultrasound 186
utility of PET scan 186
V/Q scan in pulmonary embolism 189
ventilation-perfusion scintiscanning 188
Radiometric methods 520
Radionuclide scans 1332
Radiotherapy planning 185
Rapid diagnosis of MDR- and XDR-TB 525
Rapid methods of detection of tuberculosis 523
molecular methods 524
Rapidly growing mycobacteria 798
Recent advances in chemotherapy and novel targeted therapy for lung cancer 1345
Recent trends 1297
Recommended modes of therapy 1348
Recording and reporting 609
at the PHI-level, following report is generated 611
forms 609
registers 610
reports 611
Reducing antibiotic pressure 1782
AB rotation or cycling policy 1782
rationalize AB prescription practices 1782
restricting the use of antibiotics 1782
selective decontamination of digestive tract 1782
using narrow spectrum AB 1782
Reduction in other risk factors 1160
Referred pain 23
Rehabilitation 1137
Rejection 1693
Relapse 545
Renal failure 549, 600
Renal impairment 715
Renal toxicity 718
Resistance 243
control 246
evolution of resistance 244
mechanism of resistance 244
resistant microorganisms important in respiratory diseases 245
Respiration 64
Respiratory acidosis 91
Respiratory airspace enlargement 1086
Respiratory alkalosis 92
Respiratory bronchiolitis associated interstitial lung disease 1254
Respiratory cycle 72
Respiratory exchange ratio 66
Respiratory failure 512
Respiratory motor command corollary discharge 25
Respiratory muscle abnormalities 27
Respiratory muscle effort 72
Respiratory muscle weakness 1450
Respiratory muscles 924
Respiratory problems in coalworkers 1483
Respiratory stimulants 1142
Respiratory symptoms 1144
Respiratory syncytial virus pneumonia 382
clinical features 382
treatment 383
Respiratory system 447
Respiratory tract (postnatal life) 46
Respiratory tract infections 280
Reversibility test 197
Reversibility test (bronchodilator test) 197
method 198
Revised national TB control program and treatment of pediatric tuberculosis 1720
chemoprophylaxis 1722
diagnosis 1721
general issues 1722
monitoring and evaluation 1722
operational research issues 1722
treatment of pediatric TB 1721
Revised national tuberculosis control programme in India-DOTS and DOTS plus 585
district level 589
extent of the tuberculosis problem 585
national level 587
objectives of the revised national tuberculosis control programme 586
organizational structure and functions 587
organizational structure: central level 587
peripheral health institutions 589
sputum collection centers 591
state level 588
structure of RNTCP at the state level 588
Rheumatoid arthritis 433, 1439
bronchiolitis and bronchiectasis 1442
Caplan’s syndrome 1442
cricoarytenoid arthritis 1443
interstitial lung disease 1440
lung cancer 1443
lung disease due to drugs used for RA 1443
other pulmonary problems 1443
pleural involvement 1440
pulmonary arteritis and pulmonary hypertension 1442
pulmonary function changes 1443
radiological findings of RA 1443
rheumatoid nodules/necrobiotic nodules 1441
upper lobe fibrobullous disease 1442
Rheumatoid nodules 1441
Rhinitis 994
allergic bronchopulmonary aspergillosis 994
aspirin intolerant asthma 994
Rib abnormalities 1660
Rifampin (rifampicin) 533
Rifamycin derivatives 540
RNTCP category IV regimen: second-line anti-TB drugs 725
RNTCP DOTS-plus 747
DOTS-plus site committee 747
intermediate reference laboratories 747
national DOTS-plus committee 747
national reference laboratories 747
state DOTS plus committee 747
RNTCP DOTS-plus recording and reporting system 728
aims of the information system 728
computerized systems 731
objectives 728
records, reports and flow of information 728
culture conversion report of category IV cases 730
DOTS-plus treatment card 728
laboratory registers 730
patient identity card 730
quarterly report of category IV (DOTS-plus) case finding 730
request forms for sputum examination, culture and DST 730
RNTCP DOTS-plus register 729
six month interim report 730
treatment outcome report of category IV cases 731
scope of the information system 728
training 731
RNTCP DOTS-plus register 729
RNTCP treatment categories and regimens for children 604
Role of environmental agents 1388
Role of genetic factors 1387
Romones (cromolyn sodium and nedocromil sodium) 939
antihistamines 940
cromolyn sodium 939
ketotifen 940
nedocromil sodium 940
Rounded atelectasis 1499
S
Saccular period 44
Safety of inhaled steroids 990
Sarcoidosis 1403
Sarcoidosis in India 1386
Sarcomas 1376
SARS in children 399
Scar carcinoma 511
Schistosomiasis 863
Screening for lung cancer 1316
Secondary prevention 1025
Secondary prophylaxis 987
Secondary spontaneous pneumothorax 1598
Second-line anti-TB drug information sheets 749
Second-line art in patients with TB 566
Sedation 971
Seizure disorders 715
Selection of patients (recipients) 1691
Selective decontamination of the digestive tract 1780
Sensors 94
Sepsis 1779, 1780
Sepsis and acute lung injury 1228
Septic shock 1779
Serology 285
Serratia marcescens pneumonia 352
prevention 354
Severe acute respiratory syndrome (SARS) 397
clinical features 398
etiology 397
laboratory diagnosis 401
laboratory findings 398
pathogenesis 397
pathology 398
prevention 402
prognosis 402
radiological findings 398
SARS in children 399
treatment 401
Severe exacerbations 1023
Shrinking lung syndrome 1449
Side-effects of anti-TB drugs 685
Silhouette sign 161
Silicoproteinosis 1471
Silicosis 1464, 1476
Silicosis and tuberculosis 1471
Silicosis in India 1465
broncholiths 1475
clinical features 1471
silicoproteinosis 1471
silicosis and tuberculosis 1471
complications 1475
diagnosis 1472
mineralogic analysis 1470
pathogenesis 1467
pathology 1469
accelerated silicosis 1469
acute silicosis 1469
chronic silicosis 1469
prevention of silicosis 1476
prognosis 1476
treatment 1476
Simple or benign mountain sickness 99
Sinusitis 878, 1027
Sjögren’s syndrome 1456
airways involvement 1456
interstitial lung disease 1457
pulmonary lymphoma 1457
Skin test reactions 529
Sleep and COPD 1104
Sleep apnea syndrome 104, 106
Slides 622
Small cell carcinoma 1311
Small cell lung cancer 1336, 1348
chemotherapy 1336
immunotherapy and others 1340
radiotherapy 1338
surgery 1339
Smear microscopy 592
Smear pTB 760
Smear-negative patients 603
Smoke inhalation 1543
Smoking 215, 1304
passive smoking 1305
Smoking cessation 1160
Smoking cessation intervention process 1131
Smoking prevention and cessation 1131
Socioeconomic interventions 721
Solid fuel combustion 1157
Solitary pulmonary nodule 142
Soluble interleukin-4 receptors 983
Sore throat 1704
Spacer devices 946
Special considerations 1138
surgery in COPD 1138
Special considerations in managing asthma 1757
Special initiatives 618
public private mix 618
other health providers involved in PPM 618
Special problems in COPD 1104
COPD and air travel 1105
general approach to management of COPD 1106
outcome measurements in COPD 1108
principles of management in inpatient 1106
sleep and COPD 1104
surgery in COPD 1105
Special situations 1399
Specific therapy 19
Specimen collection 704
Specimen sources 283
Spectinomycin 263
Spiral CT 1205
Spirometric classification of severity and stages of COPD 1126
Spirometry and PEF 1139
spirometry 1129
Spontaneous pneumothorax 220
Sputum collection centers 591
Sputum container with specimen and wooden sticks 621
Sputum culture 284
Sputum microscopy 592
Sputum smear 544
Sputum specimens 704
Sputum-smear microscopy 596
Squamous cell carcinoma 1310
Stage-wise control of asthma 1020
Staging of lung cancer 1316, 1336
clinical features 332
diagnosis 333
epidemiology 331
methicillin resistant—Staphylococcus aureus 334
pathology 332
toxic shock syndrome 333
treatment 334
State task force 637
Status asthmaticus 1179
Stepping down 993
Steroid formulations 993
Steroid tablet-induced side effects 993
Steroid tablets 1003
Steroid tablet-staring medication 993
Steroid therapy 1000
Steroids in septic shock 1779
Stop TB strategy 762
vision, goal, objectives and targets 762
vision 762
Streptococcal pneumonia 337
clinical features 337
diagnosis 337
epidemiology and pathogenesis 337
treatment 337
Streptomycin 263, 536
side effects 536
Stress proteins 117
Subacute cough 19
Subacute infantile mountain sickness 101
Submucosa 52
Subunit vaccines 576
Sulbactam 260
Sulfonamides 268
Superior vena cava obstruction 1344
Supervision, monitoring and evaluation 611
assessment of impact 614
external evaluation of the program 614
millennium development goals 614
monitoring 613
national review of the program 614
prioritization of health units to be supervised 613
role of central TB division 612
Supportive therapy in ARI 1708
Suppurative aspergillosis 819
Surface tension 72
Surfactant and defense 118
Surfactant therapy 1764
Surgery and asthma 978
Surgery in tuberculosis 550
modern surgical management 550
Surgical treatments 1137
bullectomy 1137
lung transplantation 1138
lung volume reduction surgery 1138
Symptomatic treatment of lung cancer 1344
Synthesis inhibitors 941
Syringes 621
Systemic antifungal agents 834
Systemic lupus erythematosus 1445
airway involvement 1448
catastrophic antiphospholipid syndrome 1449
interstitial fibrosis 1448
lupus pneumonitis 1446
pleural involvement 1445
pulmonary embolism 1449
pulmonary hemorrhage 1447
pulmonary hypertension 1448
pulmonary infections in SLE 1449
pulmonary vascular disease 1448
respiratory muscle weakness 1450
vanishing lung syndrome or shrinking lung syndrome 1449
Systemic sclerosis 1452
T
T cell opportunists 805
T cell receptor 1391
T cell subset development 125
T cells 486
T lymphocytes 120
Talc worker’s pneumoconiosis 1539
Tartrazine and sulfite sensitivity 878
Tazobactam 260
TB burden in India 477
early host response 484
genomic structure of M. tuberculosis 481
organism 479
pathogenesis 481
pathogenetic mechanisms of tuberculosis 483
subsequent responses 485
interaction of macrophages and T cells 486
macrophages 485
other cells 487
T cells 486
TB laboratory services 589
TB lymphadenitis 605
TDI 1548
Terminal respiratory unit (acinus, primary lobule) 53
Tertiary prevention 1025
Tetracycline hydrochloride 265
Tetracyclines 265
Textile waste 1529
Theory of length-tension inappropriateness 26
Therapeutic approach in patients with asthma 947
Thermal injury 1543
Thiacetazone 538
side effects 538
Thoracentesis and pleural biopsy 1562
Thoracoscopy 218
Thorax 60
Thread mills 1529
Thromboembolism 1196
Thrombolytic therapy 1209
Thymic carcinoma 1636
Thymic cysts 1636
Thymic hyperplasia 1636
Thymic tumors 1636
Thymomas 1632
Tietze’s syndrome 1663
Tiotropium bromide 994
Tissue resistance 74
Tobacco smoke 1157
Tobramycin 263
Tonsillitis 1704
Toxic fluids 1549
Toxic gases and particulate matter 1543
Toxic shock syndrome 333
Toxoplasma gondii pneumonia 416
Trachea 48
Tracheal agenesis and atresia 1673
Tracheal diverticuli 1674
Tracheal stenosis 1673
Tracheobronchial nodes 59
Tracheobronchial secretions 112, 113
Tracheobronchial tree 1673
Tracheobronchomalacia 1676
Tracheobronchomegaly 1674
Tracheobronchopathia osteochondroplastica 1677
Tracheoesophageal fistula 1673
Tracheopathia osteoplastica 1677
Training 614
initial RNTCP training 615
initial RNTCP training for medical college staff 616
retraining schedules 617
initial training on EQA 616
initial training on TB/HIV 616
Transbronchial biopsy 223
Transbronchial needle aspiration 223
Transthoracic needle aspiration 286
Transtracheal needle aspiration 285
Transudative pleural effusions 1569
Traumatic hernias 1665
Traumatic pneumothorax 1598
Treatment delivery and adherence 720
directly observed therapy 721
maintaining confidentiality 721
early and effective management of adverse drug reactions 722
education of patients and their families 720
follow-up of non-adherent patient 722
objectives 720
social and emotional support 722
socioeconomic interventions 721
treatment delivery settings 720
adherence 721
ambulatory care 720
initial inpatient care 720
Treatment of acute asthma in children aged less than 2 years 1005
B2 agonist bronchodilators 1005
further investigation and monitoring 1005
ipratropium bromide 1005
steroid therapy 1005
Treatment of acute asthma in children aged over 2 years 1003
beta2-agonist bronchodilators 1003
further investigation and monitoring 1004
intravenous aminophylline 1004
intravenous salbutamol 1003
ipratropium bromide 1004
other therapies 1004
intravenous fluids 1004
intravenous magnesium sulphate 1004
oxygen 1003
steroid therapy 1003
inhaled steroids 1004
steroid tablets 1003
Treatment of multi-drug resistant tuberculosis 710
classes of anti-TB drugs 710
category IV regimen 710
drug dosages and administration 710
treatment duration 711
treatment outcomes 712
deciding on treatment 710
objectives 710
providing patient and family counseling 712
Treatment of Pancoast’s syndrome 1344
Treatment of patient with stable COPD 1160
Treatment of superior vena cava obstruction 1344
Treatment of tuberculosis 531
isoniazid 531
side effects 532
Treatment outcome definitions for RNTCP DOTS-plus patients 699
cohort analysis 699
culture and DST 701
diagnostic examination 701
follow-up smear and culture schedule during treatment 701
pretreatment evaluation 701
diagnosis and evaluations 701
monitoring progress during treatment 702
clinical monitoring 702
investigations during treatment 702
objectives 701
patient flow 701
Treatment under special circumstances 548
corticosteroid in tuberculosis 549
diabetes mellitus 548
liver disease 548
other disorders 549
pregnancy 548
renal failure 549
Trichinosis 848
Tropical pulmonary eosinophilia 849
clinical features 852
Tubercular pleural effusion 219
Tuberculin reaction 527
Tuberculin skin test 526
administration of test 528
classification of reaction 529
immunological basis for tuberculin reaction 527
interpretation of skin test reactions 529
use of tuberculin test 530
Tuberculin test 530
Tuberculosis and HIV infection 560
case finding 567
case holding and treatment 567
complications 574
new tuberculosis vaccines 574
prevention of tuberculosis 566
pulmonary TB and HIV 562
technique of administration 573
treatment 563
second-line ART in patients with TB 566
types of vaccine 573
Tuberculosis and respiratory failure 1180
Tuberculosis in children 1711
clinical features and diagnosis 1713
epidemiology 1711
morbidity and mortality 1713
Tuberculous endobronchitis and tracheitis 510
Tuberculous laryngitis and enteritis 510
Tuberculous pleural effusion 1571
Tularemia 376
Tumor markers/products 1335
Tumor-related sarcoid reactions 1393
Tumors of chest wall 1663
Tumors of pleura 1603
Twelve months after therapy 1272
Types of drug resistance 552
acquired (secondary) drug resistance 552
initial drug resistance 552
multi-drug resistant tuberculosis 552
primary drug resistance 552
transmitted drug resistance 552
U
Uninterrupted supply of quality-assured second-line drugs 692
recording and reporting system designed for DOTS-plus 693
Upper airway obstruction 196
Upper lobe fibrobullous disease 1442
Usual interstitial pneumonia (UIP) 1254
V
V/Q scan in pulmonary embolism 189
Vaccination 374
Vaccination approaches 575
Vaccine 573, 1136
Vancomycin 260
Vanishing lung syndrome 1449
Varicella zoster and herpes simplex virus pneumonias 391
Vasodilators 1136
Vasopressin administration 1780
Venous blood oxygen content 87
Venous blood oxygen tension 85
Venous drainage of the lung 1681
Ventilation 65, 78, 93
airway resistance 73
assessment of the mechanical and bellows attributes of lung 75
body plethysmographic method 69
dead space and alveolar ventilation 65
distribution of ventilation 78
dynamic compliance 74
elastic properties of chest wall 71
elastic properties of lung and thorax 70
forced expiratory spirogram 75
closing volume 77
forced inspiratory flow 76
maximum expiratory flow volume curve 76
peak expiratory flow rate 76
volume of isoflow 78
forced expiratory volume 75
forced vital capacity 75
gas dilution method 68
lung volumes and capacities 68
lung capacities 68
lung volumes 68
maximum breathing capacity 75
maximum voluntary ventilation 75
measurement of airway resistance 74
factors affecting airway resistance 74
sites of airway resistance 74
measurement of lung compliance 73
mechanics of ventilation 67
metabolism and respiratory exchange ratio 66
minute ventilation 65
muscles of respiration 69
expiration 69
inspiration 69
respiratory system (combined lung and chest wall) 71
events of respiratory cycle 72
interdependence in lungs 73
respiratory muscle effort 72
surface tension 72
tissue resistance 74
work of breathing 78
Ventilation in varying atmospheric conditions 97
carbon dioxide removal 103
chronic mountain sickness (Monge’s disease) 102
decompression sickness 103
diseases of high altitude 99
effects 103
high altitude 97
high altitude cerebral edema 100
management 101
mechanisms 100
treatment 101
high altitude pulmonary edema 100
inert gas narcosis 103
oxygen toxicity 103
physiological effects 98
cardiovascular effect 98
hematological changes and oxygen transport 99
lung function 98
miscellaneous changes 99
ventilation 98
problems of increased barometric pressure 103
simple or benign mountain sickness 99
subacute infantile mountain sickness 101
travel at decreased barometric pressures 102
Ventilation parameters 204
Ventilation—perfusion relationships 82
Ventilation-perfusion scintiscanning 188
Ventilator support 1776
Ventilatory drive 96
Ventilatory function in children 1700
Ventilatory impedance 33
Ventilatory management 1237
Ventilatory support 1137
Vestibulo-auditory disturbances 719
Videoassisted thoracoscopic surgery 221
Viral infections and pneumonias 377
clinical features 378
diagnosis 379
epidemiology 377
etiology 378
management 380
Viral pneumonias 396
Virtual bronchoscopy 218
Virtual bronchoscopy 218
Virus 1508
Virus-induced asthma 902
Vision 762
Voriconazole 273
W
Wastes generated by the RNTCP 621
Water balance 81
Water vapor 85
Wegener’s granulomatosis 1419
antineutrophil cytoplasmic antibodies 1421
histology 1423
imaging 1422
pathogenesis 1420
treatment 1424
Welder’s lung 1537
WHO-India guidelines 1020
WHO-india guidelines for management of COPD 1164
a practical approach at different levels of care 1164
Work of breathing 78
World free of TB 762
components of the stop TB strategy 763
address TB-HIV, MDR-TB, and the needs of poor and vulnerable populations 763
contribute to health system strengthening based on primary health care 763
empower people with TB, and communities through partnership 763
enable and promote research 763
engage all care providers 763
pursue high-quality DOTS expansion and enhancement 763
goal 762
objectives 762
targets 762
Y
Yarn manufacturing 1528
Z
Zidovudine 275
Ziehl-Neelsen staining procedure 592
classification of tuberculosis cases 593
extra-pulmonary tuberculosis 594
pleurisy is classified as extra-pulmonary TB 594
pulmonary tuberculosis 593
definition of types of cases 597
chronic 597
failure 597
new 597
others 597
relapse 597
seriousness of illness 597
treatment after default 597
determination of treatment outcomes 603
diagnostic algorithm for pulmonary TB 595
diagnostic algorithm of RNTCP 594
directly observed treatment 601
drug administration 599
external quality assessment 596
follow-up smear examination 594
hospitalization 600
treatment in patients with renal failure 600
treatment of TB during pregnancy and postnatal period 600
monitoring of patients 602
follow-up smear examination 602
new smear-positive patients 602
patient flow for DOT 601
quality assurance 595
quality assurance network in sputum-smear microscopy 596
regimen for non-DOTS treatment in RNTCP areas 599
re-treatment patients 602
side effects 600
smear-negative patients 603
treatment outcome 603
special situations 600
treatment 597
treatment in women taking oral contraceptive pills 601
treatment regimens 598
category I new sputum smear-positive 2H3R3Z3E3 + 598
DRUGS AND THEIR DOSAGE 598
ZONAL TASK FORCE 637
×
Chapter Notes

Save Clear


Physical Examination of the Respiratory SystemChapter 1

 
The aim of the physical examination of the respiratory system is to establish (a) pathology of the disease like collapse, consolidation, cavity, etc.; (b) the anatomical site of the disease, i.e. which lobe and side of the lung is involved, and (c) the possible etiology (tuberculosis, bronchogenic carcinoma, etc.) responsible for this. To achieve this, the golden rule of inspection, palpation, percussion and auscultation of the chest is to be followed in a systematic manner.
General physical examination findings pertinent to the respiratory system are as follows.
 
 
(a) Emaciation
Loss of subcutaneous fat and altered subcostal angulations are seen in patients of advanced pulmonary tuberculosis, acquired immunodeficiency syndrome, malabsorption syndrome, lung cancer and emphysema. On the other hand, apparent weight gain is noticed in cases of cor pulmonale leading on to cardiac failure. Patients of superior vena caval (SVC) obstruction will have swollen face and bloated upper half of the body. Chronic steroid therapy will also produce weight gain.
 
(b) Anemia
Patients of pulmonary tuberculosis, lung cancer, other malignancies, chronic renal failure, various infiltrative disorder of the bone marrow, suppurative lung diseases, poor nutrition and those with continued hemoptysis will have anemia of various degrees. On the other hand, suffused conjunctivae are common in secondary polycythemia and in superior vena caval obstruction.
 
(c) Lymphadenopathy
Generalized lymphadenopathy is usually a feature of tubercular lymphadenitis although the cervical group of lymph nodes are commonly affected. Other causes of generalized lymphadenopathy are: lymphomas, leukemia, HIV infection, sarcoidosis and fungal infections. Metastatic lymph nodes secondary to bronchogenic carcinoma are usually single and hard to feel on palpation and the supraclavicular lymph nodes are the commonest ones to be involved although other cervical nodes may also be affected. Axillary and inguinal lymphadenopathy secondary to lung cancer is very unusual.
 
(d) Jugular Venous Pressure
Raised jugular venous pressure is common in right-sided heart failure secondary to cor pulmonale and in pericardial effusion. The jugular vein along with other neck veins are engorged and nonpulsatile in SVC obstruction. A pulsus paradoxus of more than 10 mm Hg is seen in patients of acute exacerbations of COPD and in acute bronchial asthma. In the latter, it is an indicator of severe asthma.
 
(e) Edema
This is an evidence of either right-sided heart failure or hypoproteinemia due to poor intake, excessive loss in sputum in suppurative lung diseases and loss by the kidneys involved in secondary amyloidosis due to bronchiectasis, chronic empyema or long standing pulmonary tuberculosis.
 
(f) Cyanosis14
This is a bluish discoloration of the skin and mucous membrane due to an increase in the amount of reduced hemoglobin in the capillary blood (in excess of 5 gm/100 ml). It is the absolute amount of reduced hemoglobin rather than the relative amount which is important for the development of cyanosis. Thus, in severe anemia when the total hemoglobin is low (consequently the total reduced Hb), detection of cyanosis is difficult even if there is marked arterial desaturation. Presence of clinical cyanosis in severe anemia is a very serious situation. On the other hand, higher the hemoglobin greater is the tendency towards 2cyanosis. Thus, patients with polycythemia tend to be cyanotic at higher levels of arterial saturation. Cyanosis is most marked in the oral mucosa, lips, and undersurface of the tongue, nail beds, ears, malar eminences and the conjunctivae. The accurate detection of cyanosis may not be easy always. In some, it can be detected when the oxygen saturation drops down to 85 percent and in others it may not be detected until the saturation falls below 75 percent. The other way of cyanosis being produced, is through high extraction of oxygen in an otherwise normally saturated blood. Thus, cyanosis can be divided into 2 types: central, and peripheral. In the former, either the saturation of oxygen is low or abnormal hemoglobin is present in the blood. In the peripheral type, the saturation is normal but there is slowing of blood flow or there is higher extraction of oxygen from blood. In this type, the mucous membranes of the lips and tongue are spared. Some of the causes of cyanosis are shown in Table 1.1 below.3,4
TABLE 1.1   Causes of cyanosis
I. Central cyanosis
  1. Decreased arterial saturation
    High altitude
    Impaired lung function (COPD, interstitial lung disease, pneumonias, acute bronchial asthma and almost all other lung diseases).
    Ventilatory failure (central, pulmonary, muscular),
    Anatomic shunts in heart (congenital cyanotic heart diseases)
    Pulmonary arteriovenous fistula
    Intrapulmonary shunts
    Hemoglobin Kansas
  2. Hemoglobin abnormalities
    Met- and sulfhemoglobinemias
  3. Others
    Argyria,
    Hemochromatosis
II. Peripheral cyanosis
  • Diminished cardiac output
  • Cold exposure
  • Arterial and venous obstructions
There are certain situations when there is severe hypoxemia but no cyanosis will be detected on clinical examination. They are: severe anemia, carbon monoxide poisoning (because carboxyhemoglobin imparts a cherry red color), fever with peripheral vasodilatation (high capillary blood flow reduces oxygen extraction and minimizes cyanosis) and cosmetics, which may sometimes mask the presence of cyanosis. Pulmonary edema with cardiogenic shock will produce both central and peripheral types of cyanosis. Patent ductus arteriosus with reversed shunt will produce differential cyanosis (cyanosis in lower limbs but not in the upper). Some other causes of cyanosis due to hypoxemia is shown in Table 1.2.5
TABLE 1.2   Possible causes of hypoxemia
Hypoxia
  • Decreased inspired oxygen concentration
  • Hypobaric conditions
  • Carbon monoxide poisoning
Hypoventilation
Right-to-left shunting
  • Cardiac
    Atrioseptal defects
    Fallot's tetralogy
    Transposition of the great vessels
  • Intrapulmonary
    Arteriovenous malformations
    Pneumonias
Ventilation-perfusion mismatch
• COPD
• Bronchial asthma
• Atelectasis
• Pulmonary edema
Decreased partial pressure of oxygen in mixed venous blood
• Low cardiac output
• Shock
• Diffusion abnormalities
 
(g) Clubbing and Hypertrophic Pulmonary Osteoarthropathy (HPOA)
Hippocrates first described clubbing more than 2.500 years ago. It may be seen alone or as part of an entity called hypertrophic osteoarthropathy, which include periostitis, arthritis and sometimes thickening, and edema of the skin around the affected joints (Figs 1.1 and 1.2). Clubbing is the painless uniform swelling of the terminal phalanges of the digits.611
zoom view
FIGURE 1.1: Clubbing of fingers
3
zoom view
FIGURE 1.2: Grade 2 clubbing of fingers
Pulmonary diseases such as cancer, abscess, empyema, bronchiectasis and cystic fibrosis are the major diseases known to be associated with hypertrophic osteoarthropathy. Digestive tract cancer and cyanotic congenital heart diseases are well known association (details in Table 1.3).
Diagnosis of clubbing in its early stage is difficult and a lot of inter observer variations do exist.
TABLE 1.3   Causes of clubbing
I. Pulmonary
  • Bronchogenic carcinoma
  • Suppurative lung diseases (bronchiectasis, lung abscess, empyema)
  • Pulmonary tuberculosis (rarely but if long standing)
  • Interstitial lung disease
  • Benign mesothelioma
II. Cardiac
  • Congenital cyanotic heart diseases
  • Subacute bacterial endocarditis
  • Primary pulmonary hypertension
  • Pulmonary arteriovenous fistula
III. Gastrointestinal
  • Primary biliary cirrhosis
  • Ulcerative colitis
  • Crohn's disease
IV. Miscellaneous
  • Idiopathic
  • Familial
  • Traumatic
V. Unilateral clubbing
  • Aneurysms of arch of aorta, innominate, subclavian or ulnar arteries
  • Pressure on brachial plexus or on nerves (Pancoast's syndrome)
  • Trauma of peripheral nerves
  • Venous abnormalities (trauma, varices)
VI. Differential clubbing
  • Patent ductus arteriosus with reverse shunt (clubbing only in toes and left hand).
The earliest signs described variously are as follows:
  1. Profile sign. Profile angle is constituted between a point in the distal digital crease, Datum point (cuticle or junction point between the nail and the skin) and a point at l/3rd of the distance from the cuticle to the fingertip. Normally the angle is less than 160–180 degrees and is increased in clubbing.
  2. Hyponychial angle. This angle is constructed between a point on the distal digital crease, Datum point and the hyponychium (thickened stratum corneum lying under the free edge of nail). It is normally up to 188 degrees and is increased in clubbing. This angle is best constructed by means of a shadowgram.
Other less sensitive indicators of early clubbing are:
  1. An increase in the volume of the finger tip (normally up to 56% and measured by a plethysmograph) and
  2. An increase in the longitudinal curvature of the nail (normal 8–10 diopters).
The increase in the volume of the clubbed fingers is due to an increase in the vascular connective tissues as seen in cases of congenital cyanotic heart diseases. Many theories have attempted to explain the appearance of this sign but few have persisted. There is no accepted unified theory of the mechanism of clubbing. Obviously they will be different in different conditions. The proposed theories are: circulation of vasodilators (carbonic acid, ferritin, prostaglandins, bradykinin, 5-hydroxytryptamine and adenine nucleotides); tissue hypoxemia; neural mechanisms and genetic factors. The usual causes of clubbing are summarized in Table 1.3. Hypertrophic pulmonary osteoarthropathy affects bones and joints and is characterized by radiological signs of subperiosteal bone formation, bone pain, ankle edema, joint pain, stiffness and synovial effusion. This condition should be differentiated from hypervitaminoses A and D and fluorine toxicity where new bone formation does not occur. Clubbing occurs in about 90 percent of cases of HPOA and is usually very gross. Although HPOA can occur without clubbing, some think that the later is an essential component. Even if clubbing and HPOA have many causes in common, the prevalence differs. While clubbing is universal in congenital cyanotic heart diseases, it is common in primary biliary cirrhosis, cryptogenic fibrosing alveolitis and subacute bacterial endocarditis, HPOA is distinctly uncommon in these conditions. Proposed mechanisms of HPOA are: circulation of bioactive compounds (osteoblast stimulating factor); tissue hypoxemia; immunologic mechanisms; hormonal factors (growth hormone, altered estrogen metabolism, long acting thyroid stimulating substance-LATS and parathormone); neural mechanisms and genetic factors.12,134
zoom view
FIGURE 1.3: Telangiectasia of the tongue in pulmonary A-V malformation
Even some other findings other than those mentioned earlier will provide important clues (Fig. 1.3).
After the general physical examination, one should proceed to examine various systems.
The examination of the respiratory system will be described here in detail. One must not forget to examine the upper respiratory tract. This is the area above the trachea and can provide important clues to some diseases. The pale nasal mucosa with polyps is frequently found in cases of bronchial asthma. Short neck, hypertrophic turbinates, enlarged tonsils, adenoids and uvula, and macroglossia may be the cause of upper airways obstruction leading on to obstructive sleep apnea. Poor orodental hygiene may be the cause of aspiration pneumonias and lung abscess. Nasal ulcers may be seen in vasculitis.
 
EXAMINATION OF THE CHEST
For descriptive purposes, various areas of the chest are: supraclavicular, infraclavicular, mammary, inframammary, axillary (supra-, mid-, and infra-), suprascapular, interscapular, and infrascapular. The chest examination should be divided into inspection, palpation, percussion and auscultation.
 
 
Inspection
One should stand at the foot end of the bed and observe the patient. The respiratory rate varies from 14 to 18 per minute in normal healthy adults and is thoracoabdominal type. An increase in the rate of respiration (tachypnea) is common in many respiratory diseases including pneumonias, bronchial asthma in the acute phase, acute attacks of chronic bronchitis and emphysema, interstitial lung disease, acute respiratory distress syndrome and with many other nonrespiratory diseases. The general look of the patient like emaciation (discussed above) blue and bloated appearance (chronic bronchitis in failure), pursed lip breathing (emphysema), toxic and sick look (pneumonia and septicemia), painful catchy breathing with a fixed and immobile chest wall (pleurisy), swollen face and upper extremities (superior vena caval obstruction) audible stridor (upper airways obstruction) and wheezing (bronchial asthma) are few important observations which may give clues to the possible diagnosis. Excursion of the accessory muscles of respiration will indicate that the patient is in respiratory distress. Symmetry of the chest wall then should be looked for and is to be compared region wise on both sides. Retraction of the chest wall will mean loss of lung volume, which may be due to collapse, fibrosis or pleural thickening. Other signs of volume loss may be a drooping of the shoulder on the same side, a deformed spine with concavity towards the affected side and a lowered nipple position especially in the male. A prominent or a bulging chest wall on the other hand may be due to pleural effusion, pneumothorax or a space-occupying lesion. In either case the movement of the chest wall will be decreased. A winged scapula (scapular sign) is seen in serratus anterior muscle paralysis. Any abnormal engorged veins in the chest wall should be noted with their directions of blood flow. Puncture or biopsy mark and chest tube, if any, should provide important diagnostic clues. Paradoxical movement of the diaphragm during respiration may be present in cases of paralysis of the phrenic nerve, commonly due to bronchogenic carcinoma. Sometimes a prominent sternocleidomastoid may be apparent and will indicate the tracheal shift to the side of prominence (Trail sign).
 
Palpation
Position of the trachea is to be ascertained first during palpation and then localized tenderness (secondary deposits or pleurisy) should be looked for. Some of the other findings of inspection including movements are to be confirmed. Vocal fremitus is to be compared on identical areas on both sides. Vocal fremitus will be decreased in conditions like pleural effusion, pleural thickening, pneumothorax, collapse and fibrosis. Consolidation and a large cavity in communication with a bronchus will increase the vocal fremitus. Displacement of the apex beat will be due to a loss of lung volume (shift to the same side). Pleural effusion, pneumothorax, 5and conditions of space occupying lesions will shift the apex beat to the other side. On occasions, one may be able to palpate coarse crepitations (friction crepitus) and pleural rub (friction fremitus).
 
Percussion
The rules of percussion are: (i) Percussing finger should strike the pleximeter finger perpendicularly with the movement being from the wrist joint and should be immediately lifted up from the pleximeter. The force of percussion should be light/heavy enough (according to the area percussed and built of the patient) to just elicit the note. (ii) Percussion should be from a normal to an abnormal area or from a resonant to a less resonant area. (iii) Identical areas on both sides are to be compared. (iv) Percussion should be parallel to the border/organ to be percussed. Impaired percussion note is present in conditions like pleural effusion (note is often stony dull), pleural thickening, collapse, and fibrosis. The dullness in pleural effusion will have a rising level and it will shift (shifting dullness) unless it is loculated or the effusion is massive. Hyperresonant note is due to pneumothorax and sometimes due to a large and superficial cavity containing air or large bullae. Coin test will be positive in case of pneumothorax. If a hydropneumothorax is present, a horizontal level of dullness will be there due to fluid and above that, the area will be hyperresonant due to air. The dullness will also shift. In such cases one may hear a succussion splash. However, stomach containing fluid and air and a large cavity with fluid and air may also produce succussion splash. The levels of both the diaphragms and the cardiac borders (cardiac dullness) are to be delineated during this step of examination. Normally the lower level of the right diaphragm lies in the 6th, 8th and 10th intercostal spaces anteriorly, in the mid axillary line and in the midscapular lines respectively and the left one is about one space lower than the right. The diaphragms can move two spaces or more during respiration (usually 1 cm in normal tidal breathing but may be up to 10 cm on forced excursion). In emphysema the cardiac dullness will be obliterated and both the diaphragms lie low and are flat. The cardiac dullness may be enlarged due to pericardial effusion. The diaphragm will be placed higher than the normal positions either due to phrenic nerve palsy or injury, or be pulled up due to loss of lung volume. It may also be pushed up due to intra-abdominal causes like ascites. To differentiate between the cause of a high diaphragm due to phrenic nerve palsy and ascites, one has to do a tidal percussion to see the movement of the diaphragm during respiration. The movement will be absent or moves up rather than down during inspiration in case of phrenic nerve palsy but will be present if pushed up due to ascites.
 
Auscultation
In auscultation one should describe the nature and intensity of breath sounds, presence of adventitious sounds and the character of the vocal resonance. Normally the breath sounds are vesicular in character. This is defined as the passage of air through normal alveoli and is characterized by the inspiratory phase being longer than the expiratory phase. The last part of the expiration is not heard and there will be no gap between the two phases. Except over the trachea and a small area surrounding it, the breath sound is vesicular all over the chest. Bronchial breath sounds are due to the passage of air through the trachea and major bronchi. The most important characteristic of this sound is the hollow or aspirating character of the expiratory phase. The expiratory phase is longer or at least as long as the inspiratory phase and there will be a gap between the two-phases. The bronchial breath sound may be high-pitched or low pitched. High-pitched bronchial breath sound (tubular) is heard over an area of consolidation, collapse with a patent bronchus and over a tense pleural effusion. In the latter, the collapsed and floating lung behaves like a solid area and therefore one can hear the bronchial breathing above and medial to the pleural effusion. Low-pitched bronchial sound is heard over a cavity (a narrow opening with sudden enlargement-cavernous type). When this has a metallic overtone, it is called an amphoric breath sound. This is heard over a large superficial cavity, bronchopleural fistula and in pneumothorax with bronchial communication. In chronic obstructive airways disease, the expiratory phase may be prolonged without the change of the normal vesicular character. Intensity of the breath sound is diminished in collapse, fibrosis, pleural thickening, pleural effusion and pneumothorax. In the latter two conditions, the breath sound may be totally absent on auscultation. In interstitial fibrosis the intensity sometimes appears to be increased when the bronchi are closer to the chest wall because of the intervening interstitial and alveolar fibrosis. Adventitious sound are either rhonchi or crepitations or pleural rub. Rhonchi are musical and continuous sounds produced by the passage of air through narrowed segments of bronchi either due to bronchospasm, edema, mucus plugging or stenosis. Although there is no established criteria, these continuous sounds usually last for more than 0.25 seconds. These sounds are called sibilant rhonchi 6(wheeze) when they are high pitched and their dominant frequency is 400 Hz or more. They are more like a hissing sound. On the other hand low pitched continuous sound is more like a snoring sound and the dominant frequency is about 200 Hz or less and is called as sonorous rhonchi. While the sibilant and sonorous rhonchi are called as wheeze and rhonchus (American Thoracic Society recommendation), the British usage is high pitched and low-pitched wheeze respectively. On the other hand Laennec had called all types of adventitious sounds as rales. The usual causes are bronchial asthma, chronic bronchitis, pulmonary edema and localized obstruction (tumor and foreign body). Aspirations and pulmonary embolism may also produce rhonchi. High-pitched continuous sounds are associated with narrowing of the central airways, such as bronchospasm, edema of the airway lining, mucous plugging, and foreign bodies or tumor. When the high-pitched continuous sound is confined to inspiration or accentuated during inspiration, it is called stridor. This is a common correlate of a large airway obstruction. Lower pitched continuous sounds are usually associated with secretions in the airways and are changed markedly after cough and expectoration. Crepitations are discontinuous sounds produced by sudden opening of collapsed alveoli or due to air being passed through fluid. These sounds occur in brief bursts similar to the popping sounds of bubbles or the crackling sounds of a fire. Alternatively, they are called as crackles or rales. They are further divided into coarse and fine. Coarse crepitations are louder, lower pitched and slightly longer in duration than fine crackles. Interstitial lung diseases, early congestive cardiac failure, consolidation and fibrosis will produce fine crepitations and bronchiectasis and pulmonary edema will produce coarse crepitations. Crepitations in chronic bronchitis are either fine or coarse. Continuous sounds usually reflect abnormalities of the airways; and discontinuous sounds those of the parenchyma and /or the airways. Pleural rub has a grating or leathery character and is phasic with respiration being heard both in inspiration and expiration. It does not change with cough as may occur with crepitations and is better heard if the stethoscope is pressed firmly against the chest wall. It is usually present in pleurisy during active inflammation or even in pleural thickening if the two pleural surfaces rub against each other. Vocal resonance is the auscultatory counterpart of vocal frernitus and is more accurate than the latter. Aegophony is a characteristic sound heard like a nasal twang when the patient says one-two-three. Bronchophony is a still clearer form of vocal resonance. Whispering pectoriloquy the clear audibility of whispering sounds. All these three forms of sounds are different grades of vocal resonance and are usually heard in areas of consolidation or where one gets a bronchial breath sound. In cases of COPD, one has to note forced expiratory time (FET). The patient is asked to take a deep inspiration and then to expire as forcefully and as quickly as possible and the expiration time is noted with the stethoscope kept over the trachea. Normally this is 3 to 4 seconds and, if it exceeds 6 seconds, it indicates significant amount of airways obstruction. This roughly corresponds to a FEV1/FVC of less than 65 percent.
 
MECHANISMS OF PRODUCTION OF LUNG SOUNDS1416
Vesicular sound has a frequency content that is maximal between 100 and 300 Hz, with little energy content over 500 Hz and has a lower pitch. In most of the conducting airways gas flow is laminar and in the larger airways it is turbulent. The vibrations of the gas in the large airways are transmitted to the walls of the airways and thence to the surface of the chest and also as airborne sound towards the mouth and the periphery. As the sound travels towards the periphery and chest wall, it progressively gets filtered and attenuated. By filtration, components of sound occurring at different frequencies or pitches are transmitted differently. The transmission path acts as a low pass filter preferentially passing low frequency sounds.
Bronchial breathing contains a wide range of frequencies extending from the threshold of audibility to more than 1000 Hz. When the transmission path to the surface of the chest is altered as in consolidation, the filtering effect is decreased so that the sound over the lung fields in the periphery is same as that over the large airways. This is accompanied by alterations in the transmission of voiced sounds, which are heard more clearly over regions of consolidation (increased VR).
There is still controversy regarding the site of generation of sound. Some believe that sound is generated in the periphery.
Adventitious sounds17,18 are believed to result from abnormal motions of airway walls or materials within the airways during breathing. In contrast, normal sounds result largely from vibrations within the gas itself. Continuous sounds (rhonchi) are generated by a regular vibration or oscillation of the airway wall at one or more sites drawing energy from the airflow. The pitch of a wheeze is independent of gas density. These sounds are produced when air passing through a narrowed airway at high velocity produces a decrease in the gas pressure in the airway at the region of constriction (Bernoulli's 7principle). If allowed by the other forces acting on the airway, collapse will continue progressively until there is a substantial resistance and the flow is decreased. Then the internal pressure increases and the lumen enlarges. This alternation of the wall between almost closed and almost open can continue as long as flow rate is high enough. Crepitations are discrete vibrations that result from the sudden release of energy stored in elastic or surface forces within the lung. Fine crackles of interstitial fibrosis or early congestive cardiac failure result from the sudden release of energy stored in the lung after delayed opening during inspiration of airways that had closed at the end of the previous expiration. These crackles rarely occur in expiration and are often localized over dependent areas of the lung, where gravitational stress predisposes the airways to collapse at low lung volumes. These crepitations do not disappear after coughing. Coarse crepitations occur in pulmonary edema and bronchiectasis when fluid is found in the airways, and are probably caused by rupture of fluid films or bubbles. Crackles occur both during inspiration and expiration.
Recently a mechanism whereby sound is generated by the motion of vortices in the human lung is described. This mechanism is believed to be responsible for most of the sound, which is generated both on inspiration and expiration in normal lungs.19 Mathematical expressions for the frequencies of sound generated, which depend only upon the axial flow velocity and diameters of the bronchi, are derived. This theory allows the location within the bronchial tree from which particular sounds emanate to be determined. Redistribution of pulmonary blood volume following transition from Earth gravity to the weightless state probably alters the caliber of certain airways and sound transmission properties of the lung. It is believed that these changes can be monitored effectively and noninvasively by spectral analysis of pulmonary sound.
More recently the computer technology and minidisk recorders have been used to analyze and characterize various breath sounds.20,21
 
MORPHOLOGICAL DIAGNOSIS
By the end of the clinical examination one will have a good idea of the three-step diagnosis outlined earlier. More clues will be available from the clinical history. Common pathological diagnoses made in various pulmonary diseases are outlined in Table 1.4. Sometimes one has to make a diagnosis of more than one pathological lesion like collapse with consolidation (Table 1.4); fibrocavitary lesion when features of fibrosis and cavity are present; and effusion with collapse when the mediastinal shift occurs on the same side instead of the usual shift to the other side, a finding observed in malignant pleural effusion due to bronchogenic carcinoma.
Sometimes one finds only few fine crepitations in a localized area without any other abnormal finding, which will not fit into a particular lesion. Therefore diagnosis like infiltration, fibrosis or pneumonitis is made according to the anatomical location of these findings and associated clinical history. Some lesions like chronic bronchitis, interstitial fibrosis, and bronchiectasis are self-explanatory and need not have one of those typical described lesions.
 
ANATOMICAL DIAGNOSIS
The right lung has three lobes and the left has two. The anatomical land mark for the major fissure runs between the 2nd thoracic spine in the back along the medial border of the scapula when abducted touching its inferior angle and joining the 6th costochondral junction in the front. This fissure divides the upper and middle lobes from the lower lobe in the right and the upper lobe and the lower lobe in the left side (it has no middle lobe). The right upper and middle lobes are separated by the minor fissure, which joins the major fissure in the anterior axillary line starting from the 4th costochondral junction. The anterior segments of the upper lobes on either side lie in the infraclavicular area, the apical segments in the supraclavicular area with some posterior extension and the posterior segments lie posteriorly above the major fissure (in the left, apico-posterior segment is one bronchopulmonary segment). The middle lobe in the right is represented around the mammary area.
The lingular segments of the left upper lobe are anterior structures and correspond to the area lateral to the precordium. The lower lobe segments lie mostly posteriorly with some lateral extensions. All the lobes are represented in the axilla. Thus, one can delineate the particular segment or lobe, which is affected by the particular pathological process.
 
ETIOLOGICAL DIAGNOSIS
Clinical history and physical examination will give reliable indications regarding the possible etiology of the underlying process such as an infective process (bacterial pneumonias, tuberculosis); and malignant diseases like bronchogenic carcinoma. Thus, in most cases a diagnostic formulation like ‘collapse of right upper lobe due to bronchogenic carcinoma’; ‘fibrocavitary lesion of the left upper lobe due to tuberculosis’; ‘right sided pleural effusion due to lymphoma’ and like wise, can be made out.
8
TABLE 1.4   Pathological diagnosis of various chest lesions
Pathology
Inspection
Palpation
Percussion
Auscultation
Collapse Most commonly due to bronchogenic carcinoma
Loss of volume
(retraction, drooping of shoulder, etc.)
Diminished movement
Mediastinum shifted to same side
Impaired VF decreased
Diminished (partial) or absent (complete collapse) breath sound.
Bronchial breath sound if patent bronchus. Crepitation may be heard when a diagnosis like ‘collapse with consolidation (obstructive pneumonitis) or ‘collapse with retained secretion’ will be made.
VR decreased
Fibrosis
(tuberculosis bronchiectasis)
Same as collapse
Same as collapse
Same as collapse
Crepitations are essential findings. Differentiated from collapse by its chronicity and associated findings of cavity
Cavity
(tuberculosis, lung abscess, large bronchiectatic cavity)
May have associated findings of fibrosis
May have associated fibrosis
May or may not be impaired
Bronchial breathing (cavernous or amphoric)
Crepitations present
Suction sound present
Consolidation
(Pneumonias infarction)
No significant change
No mediastinal shift
VR increased
May be impaired
Bronchial breathing
Crepitations present
VF increased
Whispering pectoriloquy
Pleural effusion
(many causes)
Fullness of chest Diminished movement
Mediastinal shift to the opposite side VF diminished or absent
Stony-dull note Rising level of dullness
Shifting dullness +ve
Absent or diminished breath sound Bronchial breath sound may be heard at the upper border of fluid level. Also it is present in case of tense effusion VR diminished/absent Egophony may be present
Pleural thickening
Same as that of collapse
Same as that of collapse
Same as that of collapse
Absent/diminished breath sounds
VR decreased
Pleural rub may be present
Pneumothorax
Fullness
Diminished
movement
Mediastinum shifted to opposite side VF decreased
Hyperresonant note Coin test may be positive
Absent breath sound
Hydropneumothorax
Same as above Loss of lung volume if pyopneumothorax and associated pleural thickening
Mediastinal shift to otherside unless associated pleural thickening
Impaird/dull percussion note. Horizontal level of dullness Shifting dullness present
Diminished air entry/absent breath sound Succussion splash may be present VR diminished
Mass lesion
Localized bulge Diminished movement locally
Mediastinal shift will depend upon extent of involvement
Impaired/dull note
Diminished/absent breath sound Local bronchial breathing depending on continuity with bronchus VR diminished
Although most of the times this formulation is possible like a mathematical model, sometimes there may be difficulty. All the typical findings of a lesion may not be present. Therefore, one must make the best possible diagnosis by which all or most of the findings can be explained.9
REFERENCES
  1. Lupinetti FM, Wareing TH, Huddlestoa CB, et al. Pathophysiology of chronic cyanosis in a canine model. Thorac Cardiovasc Surg 1985;90:291–96.
  1. Cyanosis, hypoxia and polycythaemia. In: Braunwald E, Isselbacher KJ, Petersdorf RG, Wilson J, Martin JB, Fauci AS (Eds): Harrison's Principles of Internal Medicine (11th edn), McGraw-Hill Book Company,  NY  1987; 27,145.
  1. Armstrong C, Burak KW, Beck PL. Benzocaine-induced methemoglobinemia: A condition of which all endoscopists should be aware. Can J Gastroenterol 2004; 18:625–29.
  1. Sasidharan. P. An approach to diagnosis and management of cyanosis and tachypnea in term infants. Pediatr Clin North Am 2004;51:999–1021.
  1. Hurford WE, Kratz A. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23–2004. A 50-year-old woman with low oxygen saturation. N Engl J Med 2004;351:380–87.
  1. Lovibond JL. Diagnosis of clubbed fingers. Lancet 1938;i:363.
  1. Regan GM, Tagg B, Thomson ML. Subjective assessment and objective measurement of finger clubbing. Lancet 1967;i:530–32.
  1. Bentley D, Moore A, Schwachman H. Finger clubbing: A quantitative survey byshadowgraph. Lancet 1976;ii:164–67.
  1. Shneerson JM. Digital clubbing and hypertrophic pulmonary osteoarthropathy: The underlying mechanisms. Br J Dis Chest 1981;75:113–31.
  1. Vandemergel X, Decaux G. Review on hypertrophic osteoarthropathy and digital clubbing. Rev Med Brux 2003;24:88–94.
  1. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: Control of pain and symptoms with pamidronate. Clin Rheumatol 2004;23:330–32.
  1. Vandemergel X, Blocklet D, Decaux G. Periostitis and hypertrophic osteoarthropathy: Etiologies and bone scan patterns in 115 cases. Eur J Intern Med 2004;15:375–80.
  1. Brouwers AA, Vermeij-Keers C, van Zoelen EJ, Gooren LJ. Clubbed fingers: The claws we lost? Med Hypotheses. 2004;62:321–24.
  1. Forgacs P, Nathoo AR, Richardson HD. Breath sounds. Thorax 1971;26:288–95.
  1. Murphy RLH Jr, Holford SK. Lung sounds. Respir Care 1980;25:763.
  1. Hardin JC, Patterson JL Jr. Monitoring the state of the human airways by analysis of respiratory sound. Acta Astronaut 1979;6:1137–51.
  1. Forgacs. P. Crackles and wheezes. Lancet 1967;2:203.
  1. Levy ML, Godfrey S, Irving CS, Sheikh A, Hanekom W, Bush A, Lachman P. Wheeze detection: Recordings vs. assessment of physician and parent. J Asthma 2004; 4:845–53.
  1. Folland R, Hines E, Dutta R, Boilot P, Morgan D. Comparison of neural network predictors in the classification of tracheal-bronchial breath sounds by respiratory auscultation. Artif Intell Med 2004; 31:211–20.
  1. Sera T, Satoh S, Horinouchi H, Kobayashi K, Tanishita K. Respiratory flow in a realistic tracheostenosis model. J Biomech Eng 2003;125:461–71.
  1. Kraman SS, Wodicka GR, Kiyokawa H, Pasterkamp H. Are minidisc recorders adequate for the study of respiratory sounds? Biomed Instrum Technol 2002; 36:177–82.